

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in the treatment of osteoarthritis | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-325/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-325" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in the treatment of osteoarthritis" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in the treatment of osteoarthritis.">
            <meta name="og:description" content="Read the latest article version by Susanne Gr&auml;ssel, Dominique Muschter, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="24390">
            <meta name="article-id" content="22115">
            <meta name="dc.title" content="Recent advances in the treatment of osteoarthritis">
            <meta name="dc.description" content="Osteoarthritis (OA) is one of the most debilitating diseases and is associated with a high personal and socioeconomic burden. So far, there is no therapy available that effectively arrests structural deterioration of cartilage and bone or is able to successfully reverse any of the existing structural defects. Efforts to identify more tailored treatment options led to the development of strategies that enabled the classification of patient subgroups from the pool of heterogeneous phenotypes that display distinct common characteristics. To this end, the classification differentiates the structural endotypes into cartilage and bone subtypes, which are predominantly driven by structure-related degenerative events. In addition, further classifications have highlighted individuals with an increased inflammatory contribution (inflammatory phenotype) and pain-driven phenotypes as well as senescence and metabolic syndrome phenotypes. Most probably, it will not be possible to classify individuals by a single definite subtype, but it might help to identify groups of patients with a predominant pathology that would more likely benefit from a specific drug or cell-based therapy. Current clinical trials addressed mainly regeneration/repair of cartilage and bone defects or targeted pro-inflammatory mediators by intra-articular injections of drugs and antibodies. Pain was treated mostly by antagonizing nerve growth factor (NGF) activity and its receptor tropomyosin-related kinase A (TrkA). Therapies targeting metabolic disorders such as diabetes mellitus and senescence/aging-related pathologies are not specifically addressing OA. However, none of these therapies has been proven to modify disease progression significantly or successfully prevent final joint replacement in the advanced disease stage. Within this review, we discuss the recent advances in phenotype-specific treatment options and evaluate their applicability for use in personalized OA therapy.">
            <meta name="dc.subject" content="Osteoarthritis, OA phenotype, therapy, inflammation, subchondral bone, cartilage, pain, metabolic syndrome, senescence">
            <meta name="dc.creator" content="Gr&auml;ssel, Susanne">
            <meta name="dc.creator" content="Muschter, Dominique">
            <meta name="dc.date" content="2020/05/04">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.22115.1">
            <meta name="dc.source" content="F1000Research 2020 9:325">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Osteoarthritis">
            <meta name="prism.keyword" content="OA phenotype">
            <meta name="prism.keyword" content="therapy">
            <meta name="prism.keyword" content="inflammation">
            <meta name="prism.keyword" content="subchondral bone">
            <meta name="prism.keyword" content="cartilage">
            <meta name="prism.keyword" content="pain">
            <meta name="prism.keyword" content="metabolic syndrome">
            <meta name="prism.keyword" content="senescence">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/05/04">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="325">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.22115.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-325">
            <meta name="citation_title" content="Recent advances in the treatment of osteoarthritis">
            <meta name="citation_abstract" content="Osteoarthritis (OA) is one of the most debilitating diseases and is associated with a high personal and socioeconomic burden. So far, there is no therapy available that effectively arrests structural deterioration of cartilage and bone or is able to successfully reverse any of the existing structural defects. Efforts to identify more tailored treatment options led to the development of strategies that enabled the classification of patient subgroups from the pool of heterogeneous phenotypes that display distinct common characteristics. To this end, the classification differentiates the structural endotypes into cartilage and bone subtypes, which are predominantly driven by structure-related degenerative events. In addition, further classifications have highlighted individuals with an increased inflammatory contribution (inflammatory phenotype) and pain-driven phenotypes as well as senescence and metabolic syndrome phenotypes. Most probably, it will not be possible to classify individuals by a single definite subtype, but it might help to identify groups of patients with a predominant pathology that would more likely benefit from a specific drug or cell-based therapy. Current clinical trials addressed mainly regeneration/repair of cartilage and bone defects or targeted pro-inflammatory mediators by intra-articular injections of drugs and antibodies. Pain was treated mostly by antagonizing nerve growth factor (NGF) activity and its receptor tropomyosin-related kinase A (TrkA). Therapies targeting metabolic disorders such as diabetes mellitus and senescence/aging-related pathologies are not specifically addressing OA. However, none of these therapies has been proven to modify disease progression significantly or successfully prevent final joint replacement in the advanced disease stage. Within this review, we discuss the recent advances in phenotype-specific treatment options and evaluate their applicability for use in personalized OA therapy.">
            <meta name="citation_description" content="Osteoarthritis (OA) is one of the most debilitating diseases and is associated with a high personal and socioeconomic burden. So far, there is no therapy available that effectively arrests structural deterioration of cartilage and bone or is able to successfully reverse any of the existing structural defects. Efforts to identify more tailored treatment options led to the development of strategies that enabled the classification of patient subgroups from the pool of heterogeneous phenotypes that display distinct common characteristics. To this end, the classification differentiates the structural endotypes into cartilage and bone subtypes, which are predominantly driven by structure-related degenerative events. In addition, further classifications have highlighted individuals with an increased inflammatory contribution (inflammatory phenotype) and pain-driven phenotypes as well as senescence and metabolic syndrome phenotypes. Most probably, it will not be possible to classify individuals by a single definite subtype, but it might help to identify groups of patients with a predominant pathology that would more likely benefit from a specific drug or cell-based therapy. Current clinical trials addressed mainly regeneration/repair of cartilage and bone defects or targeted pro-inflammatory mediators by intra-articular injections of drugs and antibodies. Pain was treated mostly by antagonizing nerve growth factor (NGF) activity and its receptor tropomyosin-related kinase A (TrkA). Therapies targeting metabolic disorders such as diabetes mellitus and senescence/aging-related pathologies are not specifically addressing OA. However, none of these therapies has been proven to modify disease progression significantly or successfully prevent final joint replacement in the advanced disease stage. Within this review, we discuss the recent advances in phenotype-specific treatment options and evaluate their applicability for use in personalized OA therapy.">
            <meta name="citation_keywords" content="Osteoarthritis, OA phenotype, therapy, inflammation, subchondral bone, cartilage, pain, metabolic syndrome, senescence">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Susanne Gr&auml;ssel">
            <meta name="citation_author_institution" content="Department of Orthopedic Surgery, Exp. Orthopedics, ZMB/Biopark 1, Am Biopark 9, University of Regensburg, Regensburg, 93053, Germany">
            <meta name="citation_author" content="Dominique Muschter">
            <meta name="citation_author_institution" content="Department of Orthopedic Surgery, Exp. Orthopedics, ZMB/Biopark 1, Am Biopark 9, University of Regensburg, Regensburg, 93053, Germany">
            <meta name="citation_publication_date" content="2020/05/04">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="325">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.22115.1">
            <meta name="citation_firstpage" content="325">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-325/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-325.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=24390 /> <input type=hidden id=articleId name=articleId value=22115 /> <input type=hidden id=xmlUrl value="/articles/9-325/v1/xml"/> <input type=hidden id=xmlFileName value="-9-325-v1.xml"> <input type=hidden id=article_uuid value=cda9bc96-cd88-418c-a74f-bc7806bc036b /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in the treatment of osteoarthritis"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.22115.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.22115.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-325"
  },
  "headline": "Recent advances in the treatment of osteoarthritis",
  "datePublished": "2020-05-04T15:34:01",
  "dateModified": "2020-05-04T15:34:01",
  "author": [
    {
      "@type": "Person",
      "name": "Susanne Gr&auml;ssel"
    },    {
      "@type": "Person",
      "name": "Dominique Muschter"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Osteoarthritis (OA) is one of the most debilitating diseases and is associated with a high personal and socioeconomic burden. So far, there is no therapy available that effectively arrests structural deterioration of cartilage and bone or is able to successfully reverse any of the existing structural defects. Efforts to identify more tailored treatment options led to the development of strategies that enabled the classification of patient subgroups from the pool of heterogeneous phenotypes that display distinct common characteristics. To this end, the classification differentiates the structural endotypes into cartilage and bone subtypes, which are predominantly driven by structure-related degenerative events. In addition, further classifications have highlighted individuals with an increased inflammatory contribution (inflammatory phenotype) and pain-driven phenotypes as well as senescence and metabolic syndrome phenotypes. Most probably, it will not be possible to classify individuals by a single definite subtype, but it might help to identify groups of patients with a predominant pathology that would more likely benefit from a specific drug or cell-based therapy. Current clinical trials addressed mainly regeneration/repair of cartilage and bone defects or targeted pro-inflammatory mediators by intra-articular injections of drugs and antibodies. Pain was treated mostly by antagonizing nerve growth factor (NGF) activity and its receptor tropomyosin-related kinase A (TrkA). Therapies targeting metabolic disorders such as diabetes mellitus and senescence/aging-related pathologies are not specifically addressing OA. However, none of these therapies has been proven to modify disease progression significantly or successfully prevent final joint replacement in the advanced disease stage. Within this review, we discuss the recent advances in phenotype-specific treatment options and evaluate their applicability for use in personalized OA therapy."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-325/v1",
            "name": "Recent advances in the treatment of osteoarthritis"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in the treatment of osteoarthritis </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=24390 data-id=22115 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22115.1" data-recommended="" data-doi="10.12688/f1000research.22115.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-325/v1/pdf?article_uuid=cda9bc96-cd88-418c-a74f-bc7806bc036b" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-22115-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-22115-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-22115-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Grässel S and Muschter D. Recent advances in the treatment of osteoarthritis [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):325 (<a class=new-orange href="https://doi.org/10.12688/f1000research.22115.1" target=_blank>https://doi.org/10.12688/f1000research.22115.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-22115-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=22115 id=track-article-signin-22115 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22115?target=/articles/9-325/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24390 /> <input name=articleId type=hidden value=22115 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in the treatment of osteoarthritis</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:susanne.graessel@klinik.uni-regensburg.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Susanne Gr&auml;ssel</span></a><a href="https://orcid.org/0000-0002-2549-8285" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-2549-8285</div>,&nbsp;</span><span class="">Dominique Muschter</span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:susanne.graessel@klinik.uni-regensburg.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Susanne Gr&auml;ssel</span></a><a href="http://orcid.org/0000-0002-2549-8285" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-2549-8285</div>,&nbsp;</span><span class="">Dominique Muschter</span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 04 May 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.22115.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Orthopedic Surgery, Exp. Orthopedics, ZMB/Biopark 1, Am Biopark 9, University of Regensburg, Regensburg, 93053, Germany<br/> <p> <div class=margin-bottom> Susanne Gr&auml;ssel <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Dominique Muschter <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=66726-62614></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=66725-62616></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=66724-62615></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Osteoarthritis (OA) is one of the most debilitating diseases and is associated with a high personal and socioeconomic burden. So far, there is no therapy available that effectively arrests structural deterioration of cartilage and bone or is able to successfully reverse any of the existing structural defects. Efforts to identify more tailored treatment options led to the development of strategies that enabled the classification of patient subgroups from the pool of heterogeneous phenotypes that display distinct common characteristics. To this end, the classification differentiates the structural endotypes into cartilage and bone subtypes, which are predominantly driven by structure-related degenerative events. In addition, further classifications have highlighted individuals with an increased inflammatory contribution (inflammatory phenotype) and pain-driven phenotypes as well as senescence and metabolic syndrome phenotypes. Most probably, it will not be possible to classify individuals by a single definite subtype, but it might help to identify groups of patients with a predominant pathology that would more likely benefit from a specific drug or cell-based therapy. Current clinical trials addressed mainly regeneration/repair of cartilage and bone defects or targeted pro-inflammatory mediators by intra-articular injections of drugs and antibodies. Pain was treated mostly by antagonizing nerve growth factor (NGF) activity and its receptor tropomyosin-related kinase A (TrkA). Therapies targeting metabolic disorders such as diabetes mellitus and senescence/aging-related pathologies are not specifically addressing OA. However, none of these therapies has been proven to modify disease progression significantly or successfully prevent final joint replacement in the advanced disease stage. Within this review, we discuss the recent advances in phenotype-specific treatment options and evaluate their applicability for use in personalized OA therapy. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Osteoarthritis, OA phenotype, therapy, inflammation, subchondral bone, cartilage, pain, metabolic syndrome, senescence </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Susanne Gr&auml;ssel (<a href="mailto:susanne.graessel@klinik.uni-regensburg.de">susanne.graessel@klinik.uni-regensburg.de</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Susanne Grässel </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was funded by the German Research Foundation (DFG) as part of subproject 4 (GR1301/19-1 and -2) of the Research Consortium ExCarBon/FOR 2407/1 and 2. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Grässel S and Muschter D. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Grässel S and Muschter D. Recent advances in the treatment of osteoarthritis [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):325 (<a href="https://doi.org/10.12688/f1000research.22115.1" target=_blank>https://doi.org/10.12688/f1000research.22115.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 04 May 2020, <b>9</b>(F1000 Faculty Rev):325 (<a href="https://doi.org/10.12688/f1000research.22115.1" target=_blank>https://doi.org/10.12688/f1000research.22115.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 04 May 2020, <b>9</b>(F1000 Faculty Rev):325 (<a href="https://doi.org/10.12688/f1000research.22115.1" target=_blank>https://doi.org/10.12688/f1000research.22115.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d22218e142>Introduction</h2><p class="" id=d22218e145>Osteoarthritis (OA) is a multi-factorial, mostly slowly progressing, and primarily non-inflammatory degenerative disorder of the synovial joints that is often age related and/or trauma induced. Degradative processes eventually lead to the irreversible destruction of the articular cartilage and other tissues of the joints. Although OA is the most common musculoskeletal condition worldwide that causes significant health, economic, and social problems, research efforts so far have not been able to define its exact etiology. Age-related wear of articular cartilage and subchondral bone, limb overuse, overloading and mal-alignment, genetic disorders, and metabolic syndromes (obesity, inflammatory responses, and diabetes) are important players in the onset and progression of OA<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. For many years, strong and cost-intensive efforts have been undertaken to develop therapies to improve care, quality of life, and pain relief for OA patients. Therapeutic approaches predominantly addressed symptoms and tried to modify/improve structural features of affected joint tissues. Despite this, no therapies have been able to halt or delay OA progression satisfactorily or provided effective and long-lasting symptomatic relief. Currently, joint replacement with an artificial prosthesis is the most effective measure to improve pain sensation and quality of life in patients. The development of novel therapeutic approaches targeting the osteoarthritic degradative and inflammatory processes in cartilage, synovium, or bone requires a deep understanding of the disease status of these joint tissues at the time of the intervention. It is crucial to apply therapies at the early stages of the disease prior to major structural and functional alterations in the osteochondral unit; otherwise, these interventions will not be successful<sup><a href="#ref-3">3</a></sup>. Structural and clinical features of OA are characterized by a high interpatient variability. This heterogeneity is considered to be a major factor associated with the complexity of OA and the ongoing difficulties to identify “one size fits all” therapies<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>.</p><p class="" id=d22218e166>It is accepted that defining OA subgroups based on risk factors is too simple, so it is of high clinical interest to identify specific OA phenotypes (subgroups of patients with similar clinically observable characteristics, i.e. genetic predispositions combined with environmental factors leading to tibiofemoral OA) and endotypes (disease subtypes defined functionally and pathologically by a molecular mechanism, i.e. different mechanisms leading to the same phenotype as tibiofemoral OA), which are the basis of accurate prognosis and development of personalized therapies<sup><a href="#ref-5">5</a></sup>. Several attempts have been made to group and identify OA phenotypes according to pathobiological mechanisms. Felson defines criteria for characterizing OA phenotypes via an epidemiological approach<sup><a href="#ref-4">4</a></sup>. He discriminates between generalized arthritis and joint-specific OA, secondary and primary OA, and incident and progressive OA. Another intriguing perspective is presented by Berenbaum <i>et al</i>., who provide a novel definition of OA as a “mismatch disease” commonly referred to by evolutionary biologists<sup><a href="#ref-6">6</a></sup>. This is defined as a condition that is more common today than in the past because the human body is not well adapted to certain features of modern environments. These features are high levels of physical inactivity, chronic low-grade inflammation, high body mass index, and obesogenic diets (processed foods which are high in sugar and saturated fat and low in fiber content). Other distinctions include the following phenotypes: chronic pain with central sensitization, inflammation, metabolic syndrome, bone and cartilage metabolism, and mechanical and minimal joint disease<sup><a href="#ref-7">7</a></sup>. Deveza <i>et al</i>. divide according to mechanistic subgroups including senescence, inflammation, pain, and metabolic endotypes<sup><a href="#ref-5">5</a></sup>.</p><p class="" id=d22218e196>However, one thing has to be kept in mind when trying to define subgroups of OA. Although OA can be initiated by multiple factors at multiple sites, mechanical overloading is still the key feature of its pathogenesis. Joint tissues are sensitive to physical stimuli, and OA may result from excessively aberrant or physiologically normal mechanical stresses on initially healthy or pathologically impaired articular cartilage, bone, and ligaments, respectively<sup><a href="#ref-8">8</a></sup>. Brandt <i>et al</i>. pointed out in a commentary that they feel all OA is secondary due to the accumulation of intra-articular (i.a.) stress and all OA is primarily driven by mechanical stress on the joint<sup><a href="#ref-9">9</a></sup>. They postulate a basic mechanical etiopathogenesis for common OA and would rather categorize it on the basis of the underlying mechanical abnormality like post-traumatic, failure to absorb repetitive impulsive loading, and congenital or developmental anatomic incongruities.</p><p class="" id=d22218e210>This review will select key OA pheno-endotypes according to relevant literature and current clinical trials/therapies that have been the most promising targets for recent clinical or pre-clinical studies.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22218e216>Treatments targeting articular cartilage</h2><p class="" id=d22218e219>OA is characterized by the degradation of articular cartilage and bone matrix components. Among the earliest are type II collagen and the proteoglycan aggrecan, leading to the loss of cartilage structure and function<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>. Cartilage matrix degeneration products are well investigated for drug target discovery. Several key anabolic and catabolic pathway enzymes are dysregulated in OA cartilage, providing the opportunity to identify and validate new drug targets<sup><a href="#ref-12">12</a></sup>. To this end, novel combinations addressing existing known targets may be identified. This also includes combinations of therapeutics that are anti-catabolic and those that target anabolic signaling pathways. If investigated, this might lead to identifying novel efficacious add-ons from combining known drugs and targets. For better classification, there should be discrimination between disease-modifying OA drugs (DMOADs), which target pathways of cartilage catabolism and anabolism, and regenerative strategies based on stem cells and their components.</p><div class=section><a name=d22218e233 class=n-a></a><h3 class=section-title>Anabolic drug: sprifermin</h3><p class="" id=d22218e238>A promising anabolic DMOAD is sprifermin, which is a truncated version of human FGF18 that induces chondrocyte proliferation and cartilage matrix production. The results of a phase Ib study of i.a. injected sprifermin in patients with symptomatic knee OA found a statistically significant dose-dependent reduction in loss of total femorotibial cartilage thickness compared to placebo after 12 months of follow up<sup><a href="#ref-13">13</a></sup>. Sprifermin is currently being studied in a phase II multicenter randomized dose-finding clinical study (clinicaltrials.gov: NCT01919164). The i.a. administration of 100 μg of sprifermin to participants with symptomatic radiographic knee OA every 6 or 12 months vs. placebo resulted in an improvement in total femorotibial joint cartilage thickness after a follow up period of 2 years. This improvement was statistically significant, but clinical importance was not clear. Application of a lower dose, 30 μg of sprifermin, every 6 or 12 months vs. placebo did not result in a significant difference and it was uncertain whether the response was long lasting<sup><a href="#ref-14">14</a></sup> (<a href="#T1">Table 1A</a>).</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Current OA drug targets addressing several proposed OA phenotypes.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d22218e263 class=n-a></a><thead><a name=d22218e265 class=n-a></a><tr><a name=d22218e267 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d22218e268 class=n-a></a>Target</th><th align=left colspan=1 rowspan=1 valign=top><a name=d22218e271 class=n-a></a>Drug</th><th align=left colspan=1 rowspan=1 valign=top><a name=d22218e274 class=n-a></a>Trial ID</th><th align=left colspan=1 rowspan=1 valign=top><a name=d22218e277 class=n-a></a>Affected joint</th><th align=left colspan=1 rowspan=1 valign=top><a name=d22218e280 class=n-a></a>Results</th></tr></thead><tbody><a name=d22218e284 class=n-a></a><tr><a name=d22218e286 class=n-a></a><td align=left colspan=5 rowspan=1 valign=top><a name=d22218e287 class=n-a></a><b>A) Treatments targeting cartilage</b></td></tr><tr><a name=d22218e291 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e292 class=n-a></a>Inhibition of<br class=br>cartilage matrix<br class=br>degradation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e299 class=n-a></a>MMP-inhibitor PG-116800</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e302 class=n-a></a>NCT00041756</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e305 class=n-a></a>knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e308 class=n-a></a>Termination due to<br class=br>musculoskeletal toxicity<sup><a href="#ref-12">12</a></sup></td></tr><tr><a name=d22218e316 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e317 class=n-a></a>Cartilage matrix<br class=br>regeneration</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e322 class=n-a></a>Sprifermin (truncated human<br class=br>FGF18)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e327 class=n-a></a>NCT01919164</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e330 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e333 class=n-a></a>Improvement in total<br class=br>femorotibial joint cartilage<br class=br>thickness<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup></td></tr><tr><a name=d22218e346 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e347 class=n-a></a>Cartilage matrix<br class=br>regeneration</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e352 class=n-a></a>BMP-7 or OP-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e355 class=n-a></a>NCT01133613, NCT01111045,<br class=br>NCT00456157</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e360 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e363 class=n-a></a>Pain improvement in BMP-7<br class=br>group and placebo group<sup><a href="#ref-15">15</a></sup></td></tr><tr><a name=d22218e371 class=n-a></a><td align=left colspan=5 rowspan=1 valign=top><a name=d22218e372 class=n-a></a><b>B) Treatments targeting subchondral bone</b></td></tr><tr><a name=d22218e377 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e378 class=n-a></a>Bisphosphonates/<br class=br>bone turnover</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e383 class=n-a></a>Zoledronic acid</td><td colspan=1 rowspan=1><a name=d22218e386 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e388 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e391 class=n-a></a>Reduced BML size and visual<br class=br>analogue scale pain score<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup></td></tr><tr><a name=d22218e402 class=n-a></a><td colspan=1 rowspan=1><a name=d22218e403 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e405 class=n-a></a>Risedronate</td><td colspan=1 rowspan=1><a name=d22218e408 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e410 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e413 class=n-a></a>Reduced pain in patient<br class=br>subgroup with BMLs<sup><a href="#ref-18">18</a></sup></td></tr><tr><a name=d22218e421 class=n-a></a><td colspan=1 rowspan=1><a name=d22218e422 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e424 class=n-a></a>AXS-02 (disodium zoledronate<br class=br>tetrahydrate)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e429 class=n-a></a>NCT02746068</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e432 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e435 class=n-a></a>Reduced pain in patient<br class=br>subgroup with BMLs<sup><a href="#ref-19">19</a></sup></td></tr><tr><a name=d22218e443 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e444 class=n-a></a>Inhibition of bone<br class=br>degradation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e449 class=n-a></a>Cathepsin K inhibitor MIV-711</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e452 class=n-a></a>EudraCT: 2015-003230-26, 2016-<br class=br>001096-73</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e457 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e460 class=n-a></a>Slowdown of bone and<br class=br>cartilage degeneration<sup><a href="#ref-20">20</a></sup></td></tr><tr><a name=d22218e468 class=n-a></a><td align=left colspan=5 rowspan=1 valign=top><a name=d22218e469 class=n-a></a><b>C) Treatments targeting inflammatory processes</b></td></tr><tr><a name=d22218e473 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e474 class=n-a></a>IL-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e477 class=n-a></a>Anakinra (IL-1 receptor antagonist)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e480 class=n-a></a>NCT00110916</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e483 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e486 class=n-a></a>No improvements of OA<br class=br>symptoms<sup><a href="#ref-21">21</a></sup></td></tr><tr><a name=d22218e495 class=n-a></a><td colspan=1 rowspan=1><a name=d22218e496 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e498 class=n-a></a>AMG 108 (fully human monoclonal<br class=br>antibody to IL-1R1)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e503 class=n-a></a>NCT00110942</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e506 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e509 class=n-a></a>Minimal clinical benefit<sup><a href="#ref-22">22</a></sup></td></tr><tr><a name=d22218e515 class=n-a></a><td colspan=1 rowspan=1><a name=d22218e516 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e518 class=n-a></a>Lutikizumab (anti IL-1α/β antibody)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e521 class=n-a></a>NCT02087904</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e524 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e527 class=n-a></a>No improvement in synovitis,<br class=br>minimal effect on WOMAC<br class=br>pain score<sup><a href="#ref-23">23</a></sup></td></tr><tr><a name=d22218e537 class=n-a></a><td colspan=1 rowspan=1><a name=d22218e538 class=n-a></a></td><td colspan=1 rowspan=1><a name=d22218e540 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e542 class=n-a></a>NCT02384538</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e545 class=n-a></a>Hand OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e548 class=n-a></a>No improvement in pain or imaging outcomes<sup><a href="#ref-24">24</a></sup></td></tr><tr><a name=d22218e554 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e555 class=n-a></a>Tumor necrosis<br class=br>factor-alpha</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e560 class=n-a></a>Adalimumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e563 class=n-a></a>ACTRN12612000791831</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e566 class=n-a></a>Erosive hand OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e569 class=n-a></a>No effect on pain, synovitis, or<br class=br>BMLs<sup><a href="#ref-25">25</a></sup></td></tr><tr><a name=d22218e577 class=n-a></a><td colspan=1 rowspan=1><a name=d22218e578 class=n-a></a></td><td colspan=1 rowspan=1><a name=d22218e580 class=n-a></a></td><td colspan=1 rowspan=1><a name=d22218e582 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e584 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e587 class=n-a></a>Effective pain reduction, increased physical function<sup><a href="#ref-26">26</a></sup></td></tr><tr><a name=d22218e593 class=n-a></a><td colspan=1 rowspan=1><a name=d22218e594 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e596 class=n-a></a>Etanercept</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e599 class=n-a></a>NTR1192 (EHOA)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e602 class=n-a></a>Erosive hand OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e605 class=n-a></a>No pain relief, decrease in<br class=br>serum MMP-3 levels<sup><a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup></td></tr><tr><a name=d22218e617 class=n-a></a><td colspan=1 rowspan=1><a name=d22218e618 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e620 class=n-a></a>Infliximab</td><td colspan=1 rowspan=1><a name=d22218e623 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e625 class=n-a></a>Hand OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e628 class=n-a></a>In recent-onset RA patients,<br class=br>treatment reduced progression<br class=br>of hand OA<sup><a href="#ref-29">29</a></sup></td></tr><tr><a name=d22218e638 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e639 class=n-a></a>Toll-like receptor 7/9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e642 class=n-a></a>Hydroxychloroquine</td><td colspan=1 rowspan=1><a name=d22218e645 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e647 class=n-a></a>Hand OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e650 class=n-a></a>Failed to show efficacy<sup><a href="#ref-30">30</a>,<a href="#ref-31">31</a></sup></td></tr><tr><a name=d22218e659 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e660 class=n-a></a>I-kB kinase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e663 class=n-a></a>SAR113945 (I-kB kinase inhibitor)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e666 class=n-a></a>NCT01113333, NCT01598415,<br class=br>NCT01511549, NCT01463488</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e671 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e674 class=n-a></a>No superior efficacy<sup><a href="#ref-32">32</a></sup></td></tr><tr><a name=d22218e680 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e681 class=n-a></a>p38 MAP kinase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e684 class=n-a></a>FX-005</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e687 class=n-a></a>NCT01291914</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e690 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e693 class=n-a></a>Pain relief superior to placebo</td></tr><tr><a name=d22218e696 class=n-a></a><td align=left colspan=5 rowspan=1 valign=top><a name=d22218e697 class=n-a></a><b>D) Treatments targeting pain processes</b></td></tr><tr><a name=d22218e701 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e702 class=n-a></a>NGF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e705 class=n-a></a>Tanezumab (anti-NGF antibody)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e708 class=n-a></a>NCT02697773</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e711 class=n-a></a>Knee and hip OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e714 class=n-a></a>Modest improvement in<br class=br>functional and pain scores,<br class=br>safety concerns owing to<br class=br>increased need for joint<br class=br>replacement<sup><a href="#ref-33">33</a></sup></td></tr><tr><a name=d22218e729 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e730 class=n-a></a>NGF receptor<br class=br>tropomyosin-related<br class=br>kinase A (TrkA)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e737 class=n-a></a>Pan Trk inhibitor GZ389988</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e740 class=n-a></a>NCT02424942, NCT02845271</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e743 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e746 class=n-a></a>Short-term moderate pain<br class=br>reduction compared to<br class=br>control<sup><a href="#ref-34">34</a></sup></td></tr><tr><a name=d22218e756 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e757 class=n-a></a>Transient receptor<br class=br>potential vanilloid 1<br class=br>(TRPV1) receptor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e764 class=n-a></a>Trans-capsaicin (CNTX-4975)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e767 class=n-a></a>NCT02558439</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e770 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e773 class=n-a></a>Intra-articular CNTX-4975<br class=br>reduced moderate-to-severe<br class=br>pain compared to placebo<br class=br>over 24 weeks<sup><a href="#ref-35">35</a></sup></td></tr><tr><a name=d22218e785 class=n-a></a><td colspan=1 rowspan=1><a name=d22218e786 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e788 class=n-a></a>Mavatrep (JNJ-39439335)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e791 class=n-a></a>EudraCT 2009-010961-21</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e794 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e797 class=n-a></a>Significant reduction in pain<br class=br>and improvement in function,<br class=br>but dose adjustments required<br class=br>because of altered heat<br class=br>perception and resulting<br class=br>thermal burns<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup></td></tr><tr><a name=d22218e817 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e818 class=n-a></a>Kappa-opioid<br class=br>receptor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e823 class=n-a></a>Selective agonist CR845</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e826 class=n-a></a>NCT02524197, NCT02944448</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e829 class=n-a></a>Knee and hip OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e832 class=n-a></a>Dose-dependent pain<br class=br>reduction, more effective in hip<br class=br>OA patients<sup><a href="#ref-38">38</a></sup></td></tr><tr><a name=d22218e842 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e843 class=n-a></a>Alpha calcitonin<br class=br>gene-related<br class=br>peptide</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e850 class=n-a></a>Galcanezumab (LY2951742)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e853 class=n-a></a>NCT02192190</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e856 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e859 class=n-a></a>Study was terminated owing to<br class=br>inadequate efficacy<sup><a href="#ref-39">39</a></sup></td></tr><tr><a name=d22218e867 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e868 class=n-a></a>Imidazoline<br class=br>receptor I2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e873 class=n-a></a>CR4056 (receptor ligand)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e876 class=n-a></a>EudraCT 2015-001136-37</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e879 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e882 class=n-a></a>Successful analgesia,<br class=br>especially in male and<br class=br>overweight patients associated<br class=br>with metabolic syndrome<sup><a href="#ref-40">40</a></sup></td></tr><tr><a name=d22218e895 class=n-a></a><td align=left colspan=5 rowspan=1 valign=top><a name=d22218e896 class=n-a></a><b>E) Treatments targeting metabolic syndrome</b></td></tr><tr><a name=d22218e900 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e901 class=n-a></a>Cox-2 and T2DM</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e904 class=n-a></a>Cox-2 inhibitor and metformin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e907 class=n-a></a>Taiwan National Health Insurance<br class=br>Research Database</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e912 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e915 class=n-a></a>Lower rate of receiving joint<br class=br>replacement surgery<sup><a href="#ref-41">41</a></sup></td></tr><tr><a name=d22218e923 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e924 class=n-a></a>HMG-CoA-<br class=br>Reductase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e929 class=n-a></a>Statins: simvastatin, atorvastatin,<br class=br>atorvastatin calcium, fluvastatin<br class=br>sodium, lovastatin, nystatin,<br class=br>pravastatin, pravastatin sodium,<br class=br>rosuvastatin, and rosuvastatin<br class=br>calcium</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e942 class=n-a></a>SEKOIA phase III trial</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e945 class=n-a></a>Knee OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e948 class=n-a></a>Radiological worsening<br class=br>over 3 years, regardless of<br class=br>other potential confounding<br class=br>factors<sup><a href="#ref-42">42</a></sup></td></tr><tr><a name=d22218e960 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e961 class=n-a></a>HMG-CoA-<br class=br>Reductase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e966 class=n-a></a>Statins: atorvastatin, fluvastatin,<br class=br>pravastatin, rosuvastatin, or<br class=br>simvastatin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e973 class=n-a></a>UK-based Clinical Practice<br class=br>Research Datalink</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e978 class=n-a></a>Hand OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e981 class=n-a></a>No protective effect of statins<br class=br>on the risk of developing hand<br class=br>OA<sup><a href="#ref-43">43</a></sup></td></tr><tr><a name=d22218e991 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e992 class=n-a></a>HMG-CoA-<br class=br>Reductase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e997 class=n-a></a>Statins: pravastatin, rosuvastatin,<br class=br>simvastatin, fluvastatin, lovastatin,<br class=br>and atorvastatin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e1004 class=n-a></a>Study cohorts: 1. The Malmo Diet<br class=br>and Cancer Study (MDCS)<br class=br>2. The Malmo Preventive Project<br class=br>(MPP)<br class=br>3. Swedish Mammography<br class=br>Cohort (SMC)<br class=br>4. Cohort of Swedish Men<br class=br>(COSM)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e1022 class=n-a></a>Knee or<br class=br>hip OA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22218e1027 class=n-a></a>Statin use is not associated<br class=br>with reduced risk of<br class=br>consultation or surgery for OA<br class=br>of the hip or knee<sup><a href="#ref-44">44</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d22218e1043 class=n-a></a><p id=d22218e1045> BML, bone marrow lesion; IL, interleukin; IL-1R1, interleukin 1 receptor type 1; MMP, matrix metalloproteinase; NGF, nerve growth factor; OA, osteoarthritis; RA, rheumatoid arthritis; T2DM, type 2 diabetes mellitus; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index</p></div></div></div></div><div class=section><a name=d22218e1052 class=n-a></a><h3 class=section-title>Anabolic drug: BMP-7</h3><p class="" id=d22218e1057>Another approach was the application of BMP-7, where studies have shown a pro-anabolic effect, making BMP-7 a potential candidate to promote articular cartilage repair. Three clinical trials (two phase I and one phase II) investigated the administration of BMP-7 in patients with knee OA. Two trials were completed without results being posted (NCT01133613 and NCT01111045), and one was completed with results published (NCT00456157)<sup><a href="#ref-15">15</a></sup>. There was no dose-limiting toxicity identified in the latter study. Most adverse events were mild or moderate and were similar in placebo and BMP-7 groups. Notably, overall, the outcome of the BMP-7 group was similar to the placebo group, as both groups experienced a 20% improvement in pain (<a href="#T1">Table 1A</a>).</p></div><div class=section><a name=d22218e1068 class=n-a></a><h3 class=section-title>Anti-catabolic drugs: MMP inhibitors</h3><p class="" id=d22218e1073>Inhibition of MMPs, i.e. MMP-13 and aggrecanases such as ADAMTS-4 and -5, which are key proteases responsible for cartilage matrix degradation in OA<sup><a href="#ref-45">45</a>,<a href="#ref-46">46</a></sup>, might be another way to delay cartilage destruction. A human clinical trial (NCT00041756) involving knee OA patients receiving the MMP inhibitor PG-116800 (PG-530742), which has low affinity for both MMP-1 and MMP-7, was unfortunately terminated because of musculoskeletal toxicity<sup><a href="#ref-12">12</a></sup> (<a href="#T1">Table 1A</a>). The most frequent adverse effect was arthralgia (35% of patients), and 13% of patients reported hand adverse events (edema, palmar fibrosis, Dupuytren’s contracture, or persistent tendon thickness or nodules). As a result, MMP inhibitor PG-116800 has not been developed further as a treatment for knee OA<sup><a href="#ref-47">47</a></sup>. Other more MMP-13 selective compounds, such as CP-544439, AZD-8955, and WAY-170523, are under investigation, but clinical data have not been released yet<sup><a href="#ref-13">13</a></sup>. MMPs and aggrecanases are involved in cartilage matrix degradation, and a balanced activity of these proteases is critical for matrix homeostasis. An unbalanced protease activity favoring rapid cartilage matrix degradation in early OA pathogenesis might classify as an additional OA endotype, which then would qualify as a specific target for drug intervention.</p><p class="" id=d22218e1098>These data demonstrate that compounds such as sprifermin (FGF18) and BMP-7 have promising pro-anabolic effects on cartilage tissue, whereas the inhibition of catabolic factors such as proteases has not shown beneficial effects in cartilage so far owing to adverse effects (<a href="#T1">Table 1A</a>).</p></div><div class=section><a name=d22218e1106 class=n-a></a><h3 class=section-title>Regenerative therapies with stem cells</h3><p class="" id=d22218e1111>A total of 144 clinical trials investigating the therapeutic impact of stem cells on OA and on cartilage trauma have been reported to date at <a target=xrefwindow href="http://www.clinicaltrials.gov/" id=d22218e1113>www.clinicaltrials.gov</a>, suggesting regenerative medicine may be a promising therapy for future OA management. At first, case reports described the transplantation of mesenchymal stem cells (MSCs) through an invasive approach (surgery). Later, the introduction of autologous MSCs within the joint by i.a. injection, which represents a less-invasive strategy, was reported to be feasible and safe. Indeed, after i.a. injection into SCID mice, MSCs engrafted directly in the injured site, which has been suggested to avoid systemic distribution and toxicity as well as to promote longer survival of the cells<sup><a href="#ref-48">48</a></sup>. Currently, mostly autologous MSCs and adipose-derived stem cells (ASCs) are applied for knee OA therapy, but very few approaches are targeting hip OA. Almost all of the trials are phase Ia/b safety and dose-finding studies with a low number of participants. About 45 of the listed studies are completed, but only six of them report results. A total of 55 of the trials that are recruiting or not yet recruiting indicate strongly increasing interest in stem cell therapy not only for traumatic cartilage injury but also for late-stage OA.</p></div><div class=section><a name=d22218e1122 class=n-a></a><h3 class=section-title>Extracellular vesicles derived from stem cells</h3><p class="" id=d22218e1127>Our literature search shows that stem cells, specifically autologous stem cells derived from bone marrow (BMSCs) and adipose tissue (ASCs), are preferred over other cell types for regenerative strategies. However, there is doubt among surgeons and researchers about whether or not stem cells are really the optimal tool for regenerative therapy.</p><p class="" id=d22218e1130>After administration, stem cells tend to disappear quickly from the target tissue; however, their chondroprotective and immunomodulatory effects are long lasting. Presumably, the therapeutic effects are mainly mediated in a paracrine manner, as they appear to be independent of the engrafted cells<sup><a href="#ref-49">49</a></sup>. When exposed to inflammatory signals, MSCs develop and show a rich secretory profile. After stimulation of these cells with tumor necrosis factor (TNF)-α, a proteomic approach identified 118 proteins, which were differentially expressed by human ASCs<sup><a href="#ref-50">50</a></sup>. However, paracrine effects are not limited to soluble factors, as stem cells and other cell types produce extracellular vesicles (EVs), which are small phospholipid-bilayer-enclosed particles carrying many cytoplasmic components<sup><a href="#ref-51">51</a>,<a href="#ref-52">52</a></sup>. EVs play a role in a number of different cellular activities, such as communication between cells via horizontal transfer of mRNA and proteins, and they are distinguished according to size. EVs are attractive options for therapeutic use because of their unique physical and biological characteristics, which include high biocompatibility and intrinsic targeting activity<sup><a href="#ref-53">53</a></sup>. Exosomes, the most-studied group of EV, can be as small as 30–150 nm in diameter, so it may be possible for them to passively diffuse through tissues<sup><a href="#ref-54">54</a></sup>. Overall, the consensus is that stem cell secretomes and EVs applied for the treatment of cartilage pathology and knee OA had pleiotropic and overall positive effects<sup><a href="#ref-55">55</a></sup>. <i>In vitro</i>, anti-catabolic, immunomodulatory, and regenerative properties were assigned to the secretome and EVs. Pre-clinical <i>in vivo</i> studies resulted in positive effects on the joint and confirmed the effectiveness of EV injections as a minimally invasive therapy<sup><a href="#ref-56">56</a></sup>. Exosome injections partially improved the gait abnormality patterns in an OA mouse model<sup><a href="#ref-57">57</a></sup>, and MSC secretome injections provided early (day seven) pain reduction in treated mice<sup><a href="#ref-58">58</a></sup>. All together, these data support the translational potential of this regenerative approach. The promising <i>in vitro</i> and <i>in vivo</i> results support the potential of this new treatment strategy, opening up new perspectives for cell component-based therapies. EVs are proposed as next-generation biomarkers to predict the pathophysiological state of the joint<sup><a href="#ref-55">55</a></sup>, assigning an important role for EVs in future therapies for the treatment of joint disorders. Remarkably, they constitute a simpler, and most of all safer, alternative to actual cell-based therapeutic strategies, as they are cell derived but not living cells and thus cannot proliferate or form tumors. As known for cells, EVs can also be combined with scaffolds, either bound on their surface or embedded within the biomaterial matrices. Specific activation signals such as ultrasound may enable the controlled release of specific subpopulations of EVs, i.e. exosomes.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22218e1194>Therapies addressing subchondral bone</h2><p class="" id=d22218e1197>Besides nutrient supply and metabolism, physiological and non-physiological shock absorption and support of overlying cartilage are the main functions of subchondral bone<sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup>. Therefore, any changes affecting bone cell metabolism, structural integrity, and architecture might render the bone more susceptible to aberrant loading or even induce abnormal reactions to normal physiological load. OA-related changes in subchondral bone structure were long regarded as an adaptation of bone to the biomechanical changes observed in articular cartilage. Recently, several pre-clinical and clinical studies demonstrated that alterations in bone structure might even precede and instead mediate cartilage pathology<sup><a href="#ref-61">61</a>,<a href="#ref-62">62</a></sup> and that OA progression is associated with temporal changes in bone structure<sup><a href="#ref-60">60</a></sup>. In early OA, accelerated bone turnover leads to bone plate thinning and increased porosity, whereas the trabecular compartment shows increased trabecular spacing and decreased bone volume fraction. Progression of OA is accompanied by subchondral bone plate thickening, increased trabecular thickness, and increased bone volume fraction<sup><a href="#ref-60">60</a></sup>. Bone marrow lesions (BMLs), a hallmark of OA, appear early on MRI and are associated with increased pain and cartilage degeneration<sup><a href="#ref-63">63</a></sup>.</p><div class=section><a name=d22218e1226 class=n-a></a><h3 class=section-title>Therapies with bisphosphonates</h3><p class="" id=d22218e1231>Bisphosphonates (BPs) effectively slow down bone turnover by inhibiting osteoclast activity in osteoporosis, but their usability in OA remains uncertain<sup><a href="#ref-18">18</a></sup>. There are indications that a specific patient subgroup might respond to BP use: intravenous zoledronic acid successfully reduced BML size and visual analogue scale (VAS) pain score after 6 months in a randomized controlled trial, though a second multicenter trial could not confirm the results<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>. Furthermore, a meta-analysis by Vaysbrot <i>et al</i>. identified similar effects in a trial using oral risedronate treatment in a patient subgroup with BMLs<sup><a href="#ref-18">18</a></sup>. An active phase III trial (NCT02746068) using AXS-02 (disodium zoledronate tetrahydrate) in knee OA with associated BMLs provided promising results in the reduction of pain supposedly by suppression of local acid and pro-inflammatory cytokine production<sup><a href="#ref-64">64</a></sup>. The ongoing phenotype debate in OA raised the question of whether the effectiveness of BPs has been confounded owing to the heterogeneity of the patient group enrolled in clinical trials so far<sup><a href="#ref-64">64</a></sup>. Indeed, BPs might be especially beneficial in patients with BML or high bone turnover in an early state of OA. Interestingly, pharmacologic agents like BPs that directly affect osteoclast activity effectively reduced pain. Recent research identified osteoclasts as the inducers of OA bone pain by induction of sensory innervation in a murine OA model<sup><a href="#ref-65">65</a></sup>. Determination of more of these connections and more precise categorization of patient subgroups (like bone pain due to BML development or increased osteoclast activity/bone turnover) might lead to the repurposing of already existing drugs for new targets.</p></div><div class=section><a name=d22218e1266 class=n-a></a><h3 class=section-title>Drugs targeting bone cells</h3><p class="" id=d22218e1271>New therapeutic approaches include neutralization of cathepsin K, the major osteolytic protease released by osteoclasts. The “small molecule” cathepsin K inhibitor MIV-711 effectively attenuated joint pathology in a rabbit OA model<sup><a href="#ref-66">66</a></sup> and slowed bone and cartilage degeneration in a phase IIa multicenter trial of primary knee OA<sup><a href="#ref-20">20</a></sup>. With 26 weeks’ duration, the study was relatively short, and MIV-711 did not reduce pain during this time (<a href="#T1">Table 1B</a>). Denosumab, a monoclonal antibody directed against RANKL and thereby inhibiting osteoclastogenesis, is currently tested in erosive OA of interphalangeal finger joints (NCT02771860) and in knee OA (DISKO, ISRCTN96920058), but results have not been published to date. Potential new targets to address subchondral bone include TGFβ, which is elevated in OA synovial fluid<sup><a href="#ref-67">67</a></sup>. Systemic blocking of TGF prevented bone and cartilage degeneration in a rodent OA model<sup><a href="#ref-68">68</a></sup>, but targeting this specific molecule needs to take into consideration the physiological role of TGFβ as a differentiation stimulus for chondrocyte precursor cells<sup><a href="#ref-67">67</a></sup>. Furthermore, OA bone is targeted by anabolic therapies. Teriparatide, a synthetic parathyroid hormone, effectively reduced chondrocyte apoptosis and attenuated OA progression after i.a. application in a surgical rat OA model<sup><a href="#ref-69">69</a></sup>. Its effectivity is currently being evaluated in a phase II trial of knee OA (NCT03072147).</p></div><div class=section><a name=d22218e1303 class=n-a></a><h3 class=section-title>Dietary supplementation of vitamin D<sub>3</sub></h3><p class="" id=d22218e1310>Additional dietary supplementation of vitamin D<sub>3</sub> (cholecalciferol) might be an option to target and strengthen bone in OA owing to its ability to increase calcium and phosphate uptake from the gut and its direct effect on bone cell metabolism<sup><a href="#ref-70">70</a></sup>. Numerous trials for vitamin D<sub>3</sub> supplementation in OA patients can be found at clinicaltrials.gov, but there are contradictory reports about a relationship between vitamin D levels and a higher risk for OA incidence and progression<sup><a href="#ref-71">71</a></sup>. A meta-analysis of randomized controlled trials revealed a reduction in WOMAC pain and improved joint function in OA patients after vitamin D<sub>3</sub> intake, but only at a concentration of 2,000 IU<sup><a href="#ref-72">72</a></sup>. Cartilage degradation was not affected. Generally, vitamin D<sub>3</sub> intake might be beneficial for a large proportion of the population, as its deficiency is a worldwide problem and elderly people, who are also at an increased risk of OA, are often affected<sup><a href="#ref-73">73</a></sup>.</p><p class="" id=d22218e1342>Restoration of bone metabolism and structure might be a worthwhile goal because of the huge importance of this structure as a mechanic buffer for proper load perception and distribution. A detailed knowledge of timely changes in OA-related bone metabolism might enable a more precise use of bone anabolic and anti-catabolic therapies to restore or prevent bone degradation. Maintenance of bone structure and shock-absorbing abilities might prevent cartilage alterations and therefore put a hold on subsequent degradative events culminating in joint failure.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22218e1349>Treatments targeting inflammatory mediators and pathways</h2><p class="" id=d22218e1352>It is now commonly accepted that OA has an inflammatory component that might be more dominant in specific patient subgroups and joint tissues. The release of various pro-inflammatory mediators like prostaglandins, cytokines, and chemokines has been demonstrated in numerous pre-clinical OA animal models and in patients<sup><a href="#ref-74">74</a></sup>. Synovitis is a common feature of inflammatory OA, and technical progress in imaging technologies like ultrasound and MRI revealed synovitis in a large number of patients at different disease stages<sup><a href="#ref-75">75</a>,<a href="#ref-76">76</a></sup>. A plethora of triggers including aberrant mechanical forces, metabolic syndrome, increased age, and fragments of cartilage extracellular matrix (ECM) or crystals might induce the release of these mediators from various responsive joint tissue cell types. A large number of recent review articles address cells and components of the innate immune system as the main drivers of OA inflammatory processes<sup><a href="#ref-77">77</a>,<a href="#ref-78">78</a></sup>. Non-steroidal anti-inflammatory drugs and glucocorticoids are commonly used to treat OA but are not optimal owing to moderate effectiveness and serious side-effects in long-term use<sup><a href="#ref-79">79</a>,<a href="#ref-80">80</a></sup>.</p><div class=section><a name=d22218e1380 class=n-a></a><h3 class=section-title>Anti-cytokine therapy</h3><p class="" id=d22218e1385>Most biologics used to treat OA-related inflammation were developed for rheumatoid arthritis (RA), a disease associated with more pronounced inflammation. So far, biologics targeting the inflammatory cytokines interleukin (IL)-1 and -6 as well as TNF-α have not been useful in the prevention of pain or structural progression of OA (<a href="#T1">Table 1C</a>). Granulocyte/macrophage colony-stimulating factor (GM-CSF) was associated with inflammatory pain in a mouse OA model<sup><a href="#ref-81">81</a></sup> and was associated with hip OA over knee OA in a study analyzing mononuclear cell contribution to synovial inflammation<sup><a href="#ref-82">82</a></sup>. The anti-GM-CSF antibody otilimab (GSK3196165) was enrolled in a study for erosive hand OA and yielded promising results (NCT02683785)<sup><a href="#ref-83">83</a></sup>. Mavrilimumab, a GM-CSF receptor inhibitory antibody effective in RA<sup><a href="#ref-84">84</a></sup>, might therefore also have potential as an OA drug. The predominantly low-grade and non-systemic inflammation observed in OA might explain the limited success of single cytokine blockade. Concentration on specific OA subsets like erosive hand OA associated with more pronounced inflammation potentially presents a responsive patient group for anti-cytokine biologics. Identification of a single potent driver of OA inflammation seems to be difficult, and broader approaches targeting general pro-inflammatory signaling pathway components might be more favorable (<a href="#T1">Table 1C</a>).</p></div><div class=section><a name=d22218e1412 class=n-a></a><h3 class=section-title>Interference with pro-inflammatory signaling pathways</h3><p class="" id=d22218e1417>Targeting single cytokines has so far had little effect. Recent strategies aim to interfere with further upstream initiators of the pro-inflammatory signaling cascade. Hydroxychloroquine (HC), a chloroquine derivative used to treat malaria and inflammatory autoimmune disorders like RA, supposedly exerts its effects via Toll-like receptor (TLR) 7/9<sup><a href="#ref-85">85</a></sup>. Several studies using HC in hand OA have failed to show effects so far<sup><a href="#ref-30">30</a>,<a href="#ref-31">31</a></sup>, and results from a study in knee OA are not obtainable yet (NCT01645176). TLR downstream targets include molecules like MyD88, TRAF3/6, p38 MAPK, Janus kinases, and transcription factors like NF-κB<sup><a href="#ref-86">86</a></sup>. Several attempts have been made to interfere with signaling molecules to inhibit inflammation in OA. The I-κB kinase inhibitor SAR113945 was tested in four trials of knee OA (NCT01113333, NCT01598415, NCT01511549, and NCT01463488), but, though the compound showed a good safety and tolerability profile, a larger proof-of-concept study failed to show superior efficacy<sup><a href="#ref-32">32</a></sup>. A small subgroup of patients with effusion at baseline elicited a reduced WOMAC pain score after 56 days. Local delivery of a potent p38 MAPK inhibitor (PH-797804) reduced joint destruction and inflammation in a murine destabilization OA model<sup><a href="#ref-87">87</a></sup>. The efficacy of PH-797804 compared to naproxen was evaluated in a clinical trial involving knee OA patients, but the results have not yet been disclosed (NCT01102660). FX-005, another therapeutic p38 MAPK inhibitor with sustained-release kinetics, was evaluated in a phase I/II knee OA trial where it promoted pain relief superior to placebo after 4 weeks (NCT01291914) (<a href="#T1">Table 1C</a>). Direct targeting of the TLR would provide even higher upstream interference with OA immune activation, e.g. the application of a miR-21 inhibitor targeting TLR7 was able to induce long-lasting analgesia in an OA rat model<sup><a href="#ref-88">88</a></sup>. As for anti-cytokine therapy, careful evaluation of individual patient inflammatory status will probably help to identify more responsive patient subgroups or joints.</p></div><div class=section><a name=d22218e1452 class=n-a></a><h3 class=section-title>Other immune system targets</h3><p class="" id=d22218e1457>The complement system might also be a potential source of therapeutic targets for OA therapy<sup><a href="#ref-89">89</a>,<a href="#ref-90">90</a></sup>. An increasing number of drugs targeting different factors of the complement cascade are available and were tested in the clinic for various diseases<sup><a href="#ref-91">91</a></sup>, but, to the best of our knowledge, none of them has been tested in OA patients so far. Similarly, there is increasing awareness that adaptive immune mechanisms might be involved in OA pathophysiology<sup><a href="#ref-92">92</a>,<a href="#ref-93">93</a></sup>, but these insights have not been translated into therapeutic approaches so far. Identification of more immune system entities contributing to OA development and progression will provide even greater numbers of targets for potential OA therapeutics but requires meticulous analysis of timely and spatial involvement in disease-related processes.</p></div><div class=section><a name=d22218e1480 class=n-a></a><h3 class=section-title>Gene therapies</h3><p class="" id=d22218e1485>Novel genetic approaches are currently under evaluation for safety in clinical phase I studies. They include i.a. injection of recombinant adeno-associated virus type 2/5 (rAAV2.5) vector encoding IL-1 receptor antagonist (IL-1Ra) into one knee joint of patients with moderate OA of the knee (NCT02790723) and FX201, a helper-dependent non-integrating adenovirus, containing the human IL-1Ra gene under the control of an inflammation-sensitive promoter (NCT04119687). Moreover, new gene therapeutic targets include interferon (INF)-β (rAAV2.5 vector encoding human IFN-β under control of a NF-κB promoter, ART-I02) in subjects with RA or OA and active arthritis of the hand (NCT02727764) as well as XT-150, a plasmid DNA carrying a variant of the human IL-10 transgene (NCT03477487). Although results of these studies are not available yet, gene therapy offers great therapeutic potential as it is aimed at prolonged, site-specific, and controlled release of treatments in the target joints. Confining anti-cytokine or any anti-inflammatory treatment to specific joints could potentially prevent the side-effects observed with a more classic biologic treatment plan<sup><a href="#ref-94">94</a></sup>. Virus-related delivery systems might provide superior performance over classical delivery systems but, clearly, safety aspects (e.g. immunogenicity of the vector, off-target and long-term effects) have to be taken seriously and analyzed carefully in relation to effectiveness before considering any kind of genetic therapy<sup><a href="#ref-95">95</a></sup>. In general, data from an equine study using AAV2.5-delivered IL-1Ra showed promising results regarding pharmacodynamics and safety profile<sup><a href="#ref-96">96</a></sup>. As mentioned above, first-in-human clinical trials will evaluate the safety profile of gene-related therapies and will give a general hint regarding the applicability of gene therapies for OA.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22218e1504>Treatments addressing pain</h2><p class="" id=d22218e1507>Apart from structural deterioration in OA joints, pain is a dominant and probably the most debilitating hallmark of OA pathology and the <i>a priori</i> reason why patients see a physician. Huge effort has been put into OA-related pain research to identify underlying mechanisms, but, because of its complexity, no general guidelines could be identified for its effective treatment<sup><a href="#ref-97">97</a>,<a href="#ref-98">98</a></sup>. The sensation of pain in OA does not show uniform appearance among patients and during progression. The source of OA pain includes nociceptive pain komma inflammatory pain and neuropathic pain as well as processes of peripheral and central sensitization. Structural features like BMLs, synovitis, and joint effusion show a strong association with pain intensity<sup><a href="#ref-63">63</a>,<a href="#ref-99">99</a>,<a href="#ref-100">100</a></sup>.</p><p class="" id=d22218e1530>Classical treatments include the use of acetaminophen (paracetamol), NSAIDs, and opioids, which induce a plethora of unwanted side effects. Here komma we will discuss the latest developments in therapies directly targeting neuronal structures to alleviate OA pain.</p><div class=section><a name=d22218e1533 class=n-a></a><h3 class=section-title>Anti-nerve growth factor antibody treatment</h3><p class="" id=d22218e1538>A huge effort has been made in the development of therapeutics targeting nerve growth factor (NGF). NGF might be released upon mechanical stimulation or inflammatory mediators from different cell types including osteoclasts, osteocytes, chondrocytes, synovial fibroblasts, and macrophages in pre-clinical OA studies and human OA<sup><a href="#ref-100">100</a>–<a href="#ref-105">105</a></sup>. After the first promising clinical tests using anti-NGF antibodies, the FDA stopped ongoing trials owing to reports of serious adverse side effects with fast progression of OA and increased demand for knee replacement surgery. After the identification of risk factors (NSAID use) and dose modifications, the hold was lifted in 2015 and clinical trials continued (extensively reviewed in <a href="#ref-106">106</a>,<a href="#ref-107">107</a>). A new phase III trial of knee and hip OA using subcutaneous injections of tanezumab (monoclonal anti-NGF antibody) displayed modest improvements in pain and functional scores compared to control but again raised safety concerns after increased need for total joint replacement in the tanezumab group<sup><a href="#ref-33">33</a></sup>. Active immunization against NGF might provide a new alternative to target chronic pain, as demonstrated in murine OA<sup><a href="#ref-108">108</a></sup>. Although initial trials using anti-NGF antibodies looked promising, further studies are needed to warrant treatment safety.</p></div><div class=section><a name=d22218e1563 class=n-a></a><h3 class=section-title>Anti-nerve growth factor receptor strategy</h3><p class="" id=d22218e1568>New strategies to inhibit NGF-induced pain concentrate on the antagonization of its receptors tropomyosin-related kinase A (TrkA) and p75<sup>NTR</sup>. TrkA inhibition effectively reduced pain behavior in several pre-clinical OA models<sup><a href="#ref-109">109</a>,<a href="#ref-110">110</a></sup>. Various molecules have been developed to target the TrkA receptor: pan Trk inhibitor GZ389988 (NCT02424942 and NCT02845271), AR786 (allosteric selective TrkA inhibitor), ASP7962 (TrkA receptor antagonist, NCT02611466<sup><a href="#ref-111">111</a></sup>), ONO-4474 (pan Trk inhibitor), and VM902A (allosteric TrkA selective inhibitor). Only GZ389988 exhibited modest pain reduction compared to control after 4 weeks but no prolonged efficacy after 12 weeks<sup><a href="#ref-34">34</a></sup> (<a href="#T1">Table 1D</a>). NGF receptor p75<sup>NTR</sup> concentration is increased in the blood, synovial fluid, and tissue macrophages of OA patients<sup><a href="#ref-112">112</a></sup> and has been related to inflammatory pain in a rat model<sup><a href="#ref-113">113</a></sup>. LEVI-04, a p75 neurotrophin receptor fusion protein (p75NTR-Fc), is currently being investigated in a phase I clinical trial (NCT03227796), but results are not available yet.</p></div><div class=section><a name=d22218e1606 class=n-a></a><h3 class=section-title>Ion channels</h3><p class="" id=d22218e1611>Furthermore, ion channels like transient receptor potential (Trp) and Nav1.7/Nav1.8 voltage-gated sodium channels gained attention as potential drug targets<sup><a href="#ref-114">114</a>,<a href="#ref-115">115</a></sup>. TRP vanilloid 1 (TRPV1) channels expressed by sensory neurons might be targeted using receptor agonists like capsaicin or resiniferatoxin. In various animal models, these molecules resulted in long-term desensitization or nerve degradation, thus reducing pain and neuropeptide release, but conflicting observations have been reported<sup><a href="#ref-114">114</a></sup>. Currently, several active clinical trials are analyzing the use of topical and i.a. trans-capsaicin (CNTX-4975) in knee OA. Stevens <i>et al</i>. described a dose-dependent effect of i.a. CNTX-4975 that reduced pain compared to placebo over 24 weeks in patients with moderate-to-severe knee OA (<a href="#T1">Table 1D</a>)<sup><a href="#ref-35">35</a></sup>. The FDA assured Fast Track designation to CNTX-4975 for the treatment of OA knee pain in 2018. Several “small molecule” TRPV1 antagonists have been tested so far in healthy subjects but not in OA pain<sup><a href="#ref-116">116</a>,<a href="#ref-117">117</a></sup>, and some had to be stopped because of inefficiency or adverse effects, including NEO6860, which caused headache, nausea, fatigue, and increased blood pressure among other adverse effects<sup><a href="#ref-118">118</a>,<a href="#ref-119">119</a></sup>. A single dose of JNJ-39439335 (Mavatrep), a selective competitive TRPV1 receptor antagonist, was evaluated in phase I studies and successfully reduced pain and improved functional score in knee OA patients after 7 days, though future studies require dose adjustment owing to adverse events involving thermal perception<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup> (<a href="#T1">Table 1D</a>). Animal models indicate involvement of voltage-gated sodium channels Nav1.7 and Nav1.8 in pathological pain states<sup><a href="#ref-120">120</a></sup>, and A-803467, a selective Nav1.8 channel-blocking agent, disrupted nociceptive signal transmission in monoiodoacetate (MIA)-induced OA<sup><a href="#ref-121">121</a></sup>. Furthermore, Vertex’s sodium-channel blocker VX-150 showed efficacy in acute pain reduction and was granted a breakthrough therapeutic potential by the FDA, though results of a completed phase IIa clinical study have not been published yet (NCT02660424)<sup><a href="#ref-122">122</a></sup>.</p></div><div class=section><a name=d22218e1674 class=n-a></a><h3 class=section-title>Targeting peripheral opioid receptors</h3><p class="" id=d22218e1679>Opioids are effective analgesics but their use is limited due to serious adverse side effects like constipation, respiratory depression, tolerance, and dependence. Currently, new opioid receptor (OR) agonists with an improved safety profile targeting the µ, δ, and κ subtypes are in development. Selectively targeting the peripheral κ-OR might avoid side effects observed when drugs target the µ-OR. Cara Therapeutics developed the selective κ-OR agonist CR845 and evaluated its efficacy in knee and hip OA (NCT02524197 and NCT02944448), reporting dose-dependent efficacy in the reduction of pain in hip OA over knee OA<sup><a href="#ref-38">38</a></sup> (<a href="#T1">Table 1D</a>).</p></div><div class=section><a name=d22218e1690 class=n-a></a><h3 class=section-title>Evolving new targets</h3><p class="" id=d22218e1695>Pain relief might also be achieved by targeting the nociceptin/orphanin FQ peptide receptor (NOP)<sup><a href="#ref-123">123</a></sup>. Cebranopadol (GRT6005), a dual agonist for the NOP/µ-OR, proved to be safe and efficient in chronic back pain<sup><a href="#ref-124">124</a></sup> and was recently tested in patients with painful knee OA (NCT01357837 and NCT01709214). Other nerve-associated targets include the bradykinin B2 receptor (Fasitibant, NCT02205814 and NCT01091116) and the CB2 cannabinoid receptor (GW842166 [NCT00479427 and NCT00447486], LY2828360 [NCT01319929]). Direct blockade of the sensory neuropeptide α-calcitonin gene-related peptide using LY2951742 (galcanezumab) failed to reduce pain in patients with mild-to-moderate OA<sup><a href="#ref-39">39</a></sup> (<a href="#T1">Table 1D</a>). CR4056, an imidazoline-2 ligand with powerful analgesic properties, inhibited inflammation-induced PKCε phosphorylation and membrane translocation in sensory neurons<sup><a href="#ref-125">125</a></sup> and effectively reduced allodynia and hyperalgesia in two rat OA models<sup><a href="#ref-126">126</a></sup>. A recent phase II trial in knee OA patients reported successful analgesia, especially in male patients and in overweight patients associated with the metabolic phenotype<sup><a href="#ref-40">40</a></sup> (<a href="#T1">Table 1D</a>).</p><p class="" id=d22218e1729>Despite huge efforts invested in the development of new OA analgesics and although several candidates look promising and more and more potential drug targets are identified, pain reduction in OA is still relatively unsuccessful. The complex and diverse underlying mechanisms of OA pain, the timely and spatial alterations of pain types and sensitization, and the interaction of nerves and OA-related structural changes, immune reactions, and altered metabolic conditions still require more intense interdisciplinary research to achieve effective pain management.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22218e1737>Metabolic syndrome therapies related to OA</h2><p class="" id=d22218e1740>Metabolism can be altered in OA, and there are multiple metabolic components underlying metabolic dysregulation. The metabolic syndrome, characterized by excessive and long-term positive energy balance, is defined by several cardio-metabolic factors that commonly are found together with obesity, which are central adiposity, dyslipidemia, impaired fasting glucose levels, and hypertension. People with metabolic syndrome are prone to developing a variety of disorders, especially cardiovascular diseases, type 2 diabetes mellitus (T2DM), and some forms of tumor. The increase in prevalence of metabolic syndrome in industrialized nations, and an association with obesity, together with the fact that it was a rare disease in pre-industrial populations, leads to the hypothesis that the metabolic syndrome might be a major risk factor for OA nowadays<sup><a href="#ref-6">6</a>,<a href="#ref-127">127</a>,<a href="#ref-128">128</a></sup>.</p><p class="" id=d22218e1753>Besides hypertension, which seems to provide an elevated risk of knee OA<sup><a href="#ref-129">129</a></sup>, T2DM and knee OA often coexist and are known for common risk factors such as obesity and aging. The mechanical impact of excess body weight on joints may explain lower limb OA. However, it is unclear whether T2DM is linked to OA independently of excess weight and whether T2DM is involved in OA pathology. A coexistence between the occurrence of T2DM and OA was shown, but a causal link is not yet established<sup><a href="#ref-130">130</a></sup>. T2DM clearly has an unhealthy effect on OA via two pathways: (1) chronic hyperglycemia, which is connected to oxidative stress, abnormal production of pro-inflammatory cytokines and advanced glycation end products (AGEs) in joint tissues, and (2) insulin resistance, which may have local effects but may also maintain a systemic low-grade inflammatory state<sup><a href="#ref-131">131</a></sup>.</p><div class=section><a name=d22218e1768 class=n-a></a><h3 class=section-title>Metabolic targets for osteoarthritis therapy</h3><p class="" id=d22218e1773>So, are there metabolic targets known that are suitable for OA therapy? Some experimental studies show that mTOR signaling pathways can activate autophagy, which might be an effective approach for treating OA<sup><a href="#ref-119">119</a></sup>. OA chondrocytes where AMP kinase (AMPK) has been removed exhibit increased catabolic responses to pro-inflammatory cytokines and biochemical injury. These effects are attenuated by molecules that activate AMPK, indicating that decreased AMPK activity is associated with cartilage degradation<sup><a href="#ref-120">120</a>,<a href="#ref-121">121</a></sup>. Possibly, AMPK-activating drugs such as methotrexate, metformin, and sodium salicylate might be good candidates to combat OA progression. A Taiwanese study examined whether or not the use of a COX-2 inhibitor with metformin in OA patients with T2DM was related to fewer joint replacement surgeries than the use of a COX-2 inhibitor only<sup><a href="#ref-122">122</a></sup>. At the end of a 10-year follow up period, fewer joint replacement surgeries seemed to be needed in the case group compared to the control group. This outcome may be attributed to the fact that a combination therapy decreases pro-inflammatory factors associated with OA progression much more than one without metformin therapy (<a href="#T1">Table 1E</a>).</p></div><div class=section><a name=d22218e1795 class=n-a></a><h3 class=section-title>Statin usage and osteoarthritis</h3><p class="" id=d22218e1800>Some pre-clinical and clinical data are available regarding the effects of statin usage on OA progression. Farnahgi <i>et al</i>. aimed to define the effects of hypercholesterolemia on the progression of OA in a murine OA model<sup><a href="#ref-132">132</a></sup>. Surgical destabilization of the medial meniscus in knees from mice which were fed a high-cholesterol diet compared to controls led to a severe increase in OA symptoms. Doses of free cholesterol as recommended clinically resulted in overproduction of reactive oxygen species (ROS) and mitochondrial dysfunction. Hypertrophic and degradative markers were upregulated in chondrocytes, resulting in increased breakdown of the cartilage matrix. The authors reported that the severity of these diet-induced OA symptoms was reduced by the application of atorvastatin and a mitochondrial-targeting antioxidant, thus implicating that hypercholesterolemia promotes OA progression by mitochondrial dysfunction in chondrocytes, which was in part a result of increasing ROS production and apoptosis.</p><p class="" id=d22218e1810>In a post-hoc analysis of the SEKOIA trial, the impact of statin use on radiological progression in patients with radiological and symptomatic knee OA was investigated. Results demonstrated that the use of statins was related to radiological deterioration over the course of 3 years irrespective of other potentially related factors, such as obesity or T2DM hypertension, disease duration, symptom intensity and radiological severity<sup><a href="#ref-42">42</a></sup>. Another trial investigated the association between statin therapy initiation and incidence of hand OA, but no association was observed in this study<sup><a href="#ref-43">43</a></sup>. A pooled analysis based on time-to-event analysis of four population-based large cohorts demonstrated that statin use is not associated with reduced risk of consultation or surgery for OA of the hip or knee<sup><a href="#ref-44">44</a></sup> (<a href="#T1">Table 1E</a>).</p><p class="" id=d22218e1828>It appears that repurposing some drugs such as metformin might identify valuable candidates for the treatment of OA in the context of metabolic syndrome. However, clinical studies assessing the effect of other compounds, such as statins, on knee OA progression have shown conflicting results. In line with this, more data and a priori clinical studies are necessary to correlate unambiguously the increase of metabolic syndrome in modern times with OA.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22218e1835>Therapies targeting senescence and aging</h2><p class="" id=d22218e1838>Age is a key risk factor for the development of OA, and age-related changes within the joint might represent targets for therapy. Aging and OA are closely related but still occur independently of one another. Some hallmarks of aging can influence the development of OA, such as genomic instability, telomere attrition, epigenetic alterations, loss of proteolytic homeostasis, dysregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion and altered intercellular communication<sup><a href="#ref-137">137</a>,<a href="#ref-138">138</a></sup>. So far, no human clinical trials have been designed to specifically target aging-related processes, but pre-clinical studies targeting some of the age-related factors generated promising data which may lead to novel therapeutic strategies. In the meantime, there are several “senolytics” known, which have the potential to qualify as therapeutic agents to treat OA.</p><div class=section><a name=d22218e1848 class=n-a></a><h3 class=section-title>Cell cycle inhibitors</h3><p class="" id=d22218e1853>Cellular senescence leads to the senescence-associated secretory phenotype (SASP), which is characterized by cell-cycle arrest, enhanced production of pro-inflammatory cytokines and other factors<sup><a href="#ref-138">138</a></sup>, and increased expression of the cell cycle inhibitor p16<sup>Ink4a</sup><sup><a href="#ref-139">139</a></sup>. Baker <i>et al</i>. addressed the physiological relevance and effects of naturally occurring senescent cells. The authors injected a transgene, INK-ATTAC, which was previously established in their lab, into p16<sup>Ink4a</sup>-expressing cells of wild-type mice to induce apoptosis<sup><a href="#ref-140">140</a></sup>. Their study did not address OA specifically, but they convincingly demonstrated that p16<sup>Ink4a</sup>-positive cells accumulate during adulthood and have a detrimental effect on lifespan and encourage age-dependent alterations in various organs. Removing these cells could offer an attractive approach to healthy lifespan extension in joint tissues, which overexpress this cell cycle inhibitor. A direct connection to OA was tested by using the p16-3MR transgenic mouse, which harbors a p16<sup>INK4a</sup> (Cdkn2a) promoter<sup><a href="#ref-141">141</a></sup>. Introducing OA in this mouse strain after anterior cruciate ligament transection (ACLT) allowed the selective following and removal of senescent cells. I.a. injection of a senolytic molecule, UBX0101, which selectively kills senescent cells, attenuated the development of post-traumatic OA, reduced pain and the production of SASP factors, and improved the development, phenotype, and function of human OA chondrocytes in 3D pellet culture. The half-life of UBX0101 was low, preventing systemic exposure, but was still effective in blocking cartilage degradation by eliminating senescent cells rather than blocking their SASP secretion.</p><p class="" id=d22218e1887>Targeting cell cycle inhibitors appears to be an intriguing new strategy to halt OA progression by addressing a risk factor, aging, that is closely associated to OA.</p></div><div class=section><a name=d22218e1891 class=n-a></a><h3 class=section-title>Redox signal pathways and osteoarthritis</h3><p class="" id=d22218e1896>An important therapeutic target might be redox-signaling pathways and associated mitochondrial dysfunction in OA. It is accepted that increasing levels of ROS contribute to age-related diseases by promoting cellular dysfunction and abolishing physiological cell signaling pathways<sup><a href="#ref-142">142</a></sup>. The prevention of mitochondrial peroxiredoxin (PRX) 3 hyperoxidation-induced expression of mitochondrial catalase abrogated p38-mediated cell death and restored homeostatic signaling to maintain the viability of aging chondrocytes<sup><a href="#ref-143">143</a></sup>. Another promising target could be superoxide dismutase 2 (Sod2), as deletion of Sod2 enhanced the severity of OA in mice<sup><a href="#ref-144">144</a></sup>. Another interesting target for counteracting oxidative stress-induced tissue damage might be nuclear receptor erythroid 2 related factor (Nrf2). Nrf2 is a key transcription factor that regulates the expression of phase II antioxidant enzymes. These enzymes protect against oxidative stress and tissue damage. Cai and colleagues explored the role of Nrf2 in OA pathogenesis and the effects of Nrf2 acetylation for histone deacetylase inhibitor (HDACi) protection. For this, they took advantage of two murine OA models: i.a. injection of MIA and destabilization of the medial meniscus (DMM)<sup><a href="#ref-145">145</a></sup>. In order to analyze the efficacy of HDACi on protection from cartilage damage, a pan-HDACi, trichostatin A (TSA), was applied. TSA promoted the induction of Nrf2 downstream proteins in mouse joint tissues and reduced the expression of OA-associated proteins like several MMPs and pro-inflammatory cytokines. TSA markedly ameliorated the cartilage damage in both OA models but offered no significant protection in Nrf2-knockout mice, suggesting that the protective effect of HDACi on OA progression was Nrf2 dependent.</p><p class="" id=d22218e1915>Addressing redox-signaling pathways and mitochondrial dysfunction will enable exciting novel strategies to combat cellular senescence in general and thereby eliminate a major risk factor for OA: age.</p><p class="" id=d22218e1918>Antioxidants may also have bone-protective effects in OA pathology. Using a spontaneous OA model, the STR/Ort mice, Javaheri <i>et al</i>. treated these mice for 3 months with SFX-01®, a synthetic stable variant of sulforaphane, a naturally occurring antioxidant<sup><a href="#ref-146">146</a></sup>. SFX-01® treatment both modifies bone architecture in the STR/Ort mice and likely reduces OA pain and improves gait without improving articular cartilage lesion severity and occurrence of osteophytes in the joints of these mice. These findings strengthen the possibility that bone-targeting therapies with antioxidants may have some merit and exert osteotrophic effects possibly not only in OA.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22218e1932>Conclusions and open questions</h2><p class="" id=d22218e1935>For a few years, a novel concept considered OA as a multi-faceted disease involving the whole joint and not only cartilage or synovium. This offers new options to identify and develop novel therapeutics and to re-profile candidate drugs. Recent advances in OA pathology have enlightened key roles of several new pathways, which can be targeted. However, as OA is a highly heterogeneous disease, a single therapeutic targeting a single joint tissue may not be effective and no “one size fits all” drug/therapy will ever be developed. Improved patient stratification in combination with advanced DMOADs and cell-based therapies might lead to the development of personalized OA therapeutics.</p><p class="" id=d22218e1938>Attention to temporal changes in disease progression like the transition from high bone turnover in early OA to decreased bone turnover in the late stages or timely changes in the pain type requires precise knowledge of the underlying mechanistic alterations. Choosing appropriate medication for selective disease time-points might help tailor individual treatment regimens for each patient in the future. Additionally, OA might present itself with overlapping endotypes like, for instance, an inflammatory pain endotype that could benefit from a combination of pharmaceuticals addressing both pain and inflammation.</p><p class="" id=d22218e1941>Many clinical studies have been conducted in OA that address mainly structural targets like cartilage and bone in combination with reduction of inflammation and pain. In general, success was marginal, and only very few drugs, i.e. sprifermin or some BPs, resulted in improvement of joint structure and function. In addition, targeting TrkA or TRPV1 led to pain relief; however, no pharmacological treatment was able to halt or reverse OA progression long term.</p><p class="" id=d22218e1944>Data from the application of MSCs/ASCs generated some guarded optimism; however, so far, only cartilage lesions were addressed with cell-based therapies, whereas subchondral bone, tendons, and other joint tissues were not included. This is a crucial shortcoming, as OA is recognized as a whole-joint disease.</p><p class="" id=d22218e1948>One central point to be considered for all future therapeutic approaches, either regenerative or pharmacological, is the mechanical status of the joint. With this in mind, it is strongly suggested that the altered joint mechanics that cause OA are addressed in a first-line therapy. If altered OA joint mechanics are not normalized and original biomechanical pathways are not restored, it will be most likely that pharmacological or biological treatments of articular cartilage or inflammatory processes will not be efficacious. Furthermore, modulation of derailed cellular mechanoreceptive pathways might provide new opportunities to halt structural tissue deterioration. OA is not a single disease with a common pathophysiological pathway, as many pathways and risk factors lead to mechanical failure of the joint (<a href="#f1">Figure 1</a>), so identifying early OA stages would certainly be advantageous for the development of more efficient, targeted therapies. Therefore, the identification of reliable biomarkers and even more advanced imaging methods as well as stronger inter-disciplinary treatment regimens is indispensable.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/24390/9cb7641e-4664-4423-90b4-e9ebf71cbff3_figure1.gif"><img alt="9cb7641e-4664-4423-90b4-e9ebf71cbff3_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/24390/9cb7641e-4664-4423-90b4-e9ebf71cbff3_figure1.gif"></a><div class=caption><h3>Figure 1. Critical factors for the pathogenesis of OA.</h3><p id=d22218e1964>Intrinsic repair mechanisms are limited and therefore extrinsic repair support is required to restore or ameliorate joint function. DMOAD, disease-modifying osteoarthritis drug; SB, subchondral bone.</p></div></div><p class="" id=d22218e1971>Considering these central points, personalized OA therapy is the ultimate goal, and recent advances in phenotype classification and targeted drug development might provide a pool of suitable therapeutic options in the future.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d22218e1978 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d23148>References</h2><div class="section ref-list"><a name=d22218e1978 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d22218e1985 class=n-a></a>Loeser RF, Goldring SR, Scanzello CR, <i> et al.</i>: Osteoarthritis: A Disease of the Joint as an Organ. <i>Arthritis Rheum.</i> 2012; <b>64</b>(6): 1697–707. <a target=xrefwindow id=d22218e1996 href="http://www.ncbi.nlm.nih.gov/pubmed/22392533">PubMed Abstract </a> | <a target=xrefwindow id=d22218e1999 href="https://doi.org/10.1002/art.34453">Publisher Full Text </a> | <a target=xrefwindow id=d22218e2003 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3366018">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d22218e2012 class=n-a></a>Martel-Pelletier J, Barr AJ, Cicuttini FM, <i> et al.</i>: Osteoarthritis. <i>Nat Rev Dis Primers.</i> 2016; <b>2</b>: 16072. <a target=xrefwindow id=d22218e2023 href="http://www.ncbi.nlm.nih.gov/pubmed/27734845">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2026 href="https://doi.org/10.1038/nrdp.2016.72">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d22218e2035 class=n-a></a>Goldring SR, Goldring MB: Changes in the Osteochondral Unit During Osteoarthritis: Structure, Function and Cartilage-Bone Crosstalk. <i>Nat Rev Rheumatol.</i> 2016; <b>12</b>(11): 632–44. <a target=xrefwindow id=d22218e2043 href="http://www.ncbi.nlm.nih.gov/pubmed/27652499">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2046 href="https://doi.org/10.1038/nrrheum.2016.148">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d22218e2055 class=n-a></a>Felson DT: Identifying Different Osteoarthritis Phenotypes Through Epidemiology. <i>Osteoarthritis Cartilage.</i> 2010; <b>18</b>(5): 601–4. <a target=xrefwindow id=d22218e2063 href="http://www.ncbi.nlm.nih.gov/pubmed/20175975">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2066 href="https://doi.org/10.1016/j.joca.2010.01.007">Publisher Full Text </a> | <a target=xrefwindow id=d22218e2069 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3474706">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736769152"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2078 class=n-a></a>Deveza LA, Nelson AE, Loeser RF: Phenotypes of Osteoarthritis: Current State and Future Implications. <i>Clin Exp Rheumatol.</i> 2019; <b>37 Suppl 120</b>(5): 64–72. <a target=xrefwindow id=d22218e2086 href="http://www.ncbi.nlm.nih.gov/pubmed/31621574">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2089 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6936212">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736769152">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734011193"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2103 class=n-a></a>Berenbaum F, Wallace IJ, Lieberman DE, <i> et al.</i>: Modern-day Environmental Factors in the Pathogenesis of Osteoarthritis. <i>Nat Rev Rheumatol.</i> 2018; <b>14</b>(11): 674–81. <a target=xrefwindow id=d22218e2114 href="http://www.ncbi.nlm.nih.gov/pubmed/30209413">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2117 href="https://doi.org/10.1038/s41584-018-0073-x">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734011193">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d22218e2130 class=n-a></a>Dell'Isola A, Allan R, Smith SL, <i> et al.</i>: Identification of Clinical Phenotypes in Knee Osteoarthritis: A Systematic Review of the Literature. <i>BMC Musculoskelet Disord.</i> 2016; <b>17</b>(1): 425. <a target=xrefwindow id=d22218e2141 href="http://www.ncbi.nlm.nih.gov/pubmed/27733199">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2144 href="https://doi.org/10.1186/s12891-016-1286-2">Publisher Full Text </a> | <a target=xrefwindow id=d22218e2148 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5062907">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d22218e2157 class=n-a></a>Guilak F: Biomechanical Factors in Osteoarthritis. <i>Best Pract Res Clin Rheumatol.</i> 2011; <b>25</b>(6): 815–23. <a target=xrefwindow id=d22218e2165 href="http://www.ncbi.nlm.nih.gov/pubmed/22265263">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2168 href="https://doi.org/10.1016/j.berh.2011.11.013">Publisher Full Text </a> | <a target=xrefwindow id=d22218e2171 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3266544">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d22218e2180 class=n-a></a>Brandt KD, Dieppe P, Radin EL: Commentary: Is It Useful to Subset "Primary" Osteoarthritis? A Critique Based on Evidence Regarding the Etiopathogenesis of Osteoarthritis. <i>Semin Arthritis Rheum.</i> 2009; <b>39</b>(2): 81–95. <a target=xrefwindow id=d22218e2188 href="http://www.ncbi.nlm.nih.gov/pubmed/19796724">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2191 href="https://doi.org/10.1016/j.semarthrit.2009.06.001">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1104881"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2200 class=n-a></a>Goldring MB, Goldring SR: Osteoarthritis. <i>J Cell Physiol.</i> 2007; <b>213</b>(3): 626–34. <a target=xrefwindow id=d22218e2208 href="http://www.ncbi.nlm.nih.gov/pubmed/17786965">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2211 href="https://doi.org/10.1002/jcp.21258">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1104881">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d22218e2224 class=n-a></a>Goldring MB, Marcu KB: Cartilage homeostasis in health and rheumatic diseases. <i>Arthritis Res Ther.</i> 2009; <b>11</b>(3): 224. <a target=xrefwindow id=d22218e2232 href="http://www.ncbi.nlm.nih.gov/pubmed/19519926">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2235 href="https://doi.org/10.1186/ar2592">Publisher Full Text </a> | <a target=xrefwindow id=d22218e2238 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2714092">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d22218e2248 class=n-a></a>Tonge DP, Pearson MJ, Jones SW: The hallmarks of osteoarthritis and the potential to develop personalised disease-modifying pharmacological therapeutics. <i>Osteoarthritis Cartilage.</i> 2014; <b>22</b>(5): 609–21. <a target=xrefwindow id=d22218e2256 href="http://www.ncbi.nlm.nih.gov/pubmed/24632293">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2259 href="https://doi.org/10.1016/j.joca.2014.03.004">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d22218e2268 class=n-a></a>Karsdal MA, Michaelis M, Ladel C, <i> et al.</i>: Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip Lessons learned from failures and opportunities for the future. <i>Osteoarthritis Cartilage.</i> 2016; <b>24</b>(12): 2013–21. <a target=xrefwindow id=d22218e2279 href="http://www.ncbi.nlm.nih.gov/pubmed/27492463">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2282 href="https://doi.org/10.1016/j.joca.2016.07.017">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736720834"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2291 class=n-a></a>Hochberg MC, Guermazi A, Guehring H, <i> et al.</i>: Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial. <i>JAMA.</i> 2019; <b>322</b>(14): 1360–1370. <a target=xrefwindow id=d22218e2302 href="http://www.ncbi.nlm.nih.gov/pubmed/31593273">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2305 href="https://doi.org/10.1001/jama.2019.14735">Publisher Full Text </a> | <a target=xrefwindow id=d22218e2309 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6784851">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736720834">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d22218e2322 class=n-a></a>Evans CH, Kraus VB, Setton LA: Progress in intra-articular therapy. <i>Nat Rev Rheumatol.</i> 2014; <b>10</b>(1): 11–22. <a target=xrefwindow id=d22218e2330 href="https://doi.org/10.1038/nrrheum.2013.159">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d22218e2339 class=n-a></a>van Spil WE, Kubassova O, Boesen M, <i> et al.</i>: Osteoarthritis phenotypes and novel therapeutic targets. <i>Biochem Pharmacol.</i> 2019; <b>165</b>: 41–8. <a target=xrefwindow id=d22218e2350 href="http://www.ncbi.nlm.nih.gov/pubmed/30831073">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2353 href="https://doi.org/10.1016/j.bcp.2019.02.037">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d22218e2362 class=n-a></a>Laslett LL, Doré DA, Quinn SJ, <i> et al.</i>: Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. <i>Ann Rheum Dis.</i> 2012; <b>71</b>(8): 1322–8. <a target=xrefwindow id=d22218e2373 href="http://www.ncbi.nlm.nih.gov/pubmed/22355040">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2376 href="https://doi.org/10.1136/annrheumdis-2011-200970">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732267660"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2386 class=n-a></a>Vaysbrot EE, Osani MC, Musetti MC, <i> et al.</i>: Are bisphosphonates efficacious in knee osteoarthritis? A meta-analysis of randomized controlled trials. <i>Osteoarthritis Cartilage.</i> 2018; <b>26</b>(2): 154–64. <a target=xrefwindow id=d22218e2397 href="http://www.ncbi.nlm.nih.gov/pubmed/29222056">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2400 href="https://doi.org/10.1016/j.joca.2017.11.013">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732267660">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d22218e2413 class=n-a></a>Axsome Therapeutics, AXS-02. 2018. <a target=xrefwindow id=d22218e2415 href="https://axsome.com/axs-pipeline/about-axs-02/">Reference Source</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737143597"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2424 class=n-a></a>Conaghan PG, Bowes MA, Kingsbury SR, <i> et al.</i>: Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis: A Randomized, Placebo-Controlled Study. <i>Ann Intern Med.</i> 2019; <b>172</b>(2): 86–95. <a target=xrefwindow id=d22218e2435 href="https://doi.org/10.7326/M19-0675">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737143597">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d22218e2448 class=n-a></a>Chevalier X, Goupille P, Beaulieu AD, <i> et al.</i>: Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. <i>Arthritis Rheum.</i> 2009; <b>61</b>(3): 344–52. <a target=xrefwindow id=d22218e2459 href="http://www.ncbi.nlm.nih.gov/pubmed/19248129">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2462 href="https://doi.org/10.1002/art.24096">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d22218e2471 class=n-a></a>Cohen SB, Proudman S, Kivitz AJ, <i> et al.</i>: A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. <i>Arthritis Res Ther.</i> 2011; <b>13</b>(4): R125. <a target=xrefwindow id=d22218e2482 href="http://www.ncbi.nlm.nih.gov/pubmed/21801403">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2485 href="https://doi.org/10.1186/ar3430">Publisher Full Text </a> | <a target=xrefwindow id=d22218e2489 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3239365">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734877302"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2498 class=n-a></a>Fleischmann RM, Bliddal H, Blanco FJ, <i> et al.</i>: A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. <i>Arthritis Rheumatol.</i> 2019; <b>71</b>: 1056–69. <a target=xrefwindow id=d22218e2509 href="http://www.ncbi.nlm.nih.gov/pubmed/30653843">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2512 href="https://doi.org/10.1002/art.40840">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734877302">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734638833"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2526 class=n-a></a>Kloppenburg M, Peterfy C, Haugen IK, <i> et al.</i>: Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. <i>Ann Rheum Dis.</i> 2019; <b>78</b>(3): 413–20. <a target=xrefwindow id=d22218e2537 href="http://www.ncbi.nlm.nih.gov/pubmed/30552176">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2540 href="https://doi.org/10.1136/annrheumdis-2018-213336">Publisher Full Text </a> | <a target=xrefwindow id=d22218e2544 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6390132">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734638833">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d22218e2557 class=n-a></a>Aitken D, Laslett LL, Pan F, <i> et al.</i>: A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial. <i>Osteoarthritis Cartilage.</i> 2018; <b>26</b>(7): 880–7. <a target=xrefwindow id=d22218e2568 href="http://www.ncbi.nlm.nih.gov/pubmed/29499287">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2571 href="https://doi.org/10.1016/j.joca.2018.02.899">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d22218e2580 class=n-a></a>Wang J: Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial. <i>J Int Med Res.</i> 2017; <b>46</b>(1): 326–34. <a target=xrefwindow id=d22218e2588 href="http://www.ncbi.nlm.nih.gov/pubmed/28840750">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2591 href="https://doi.org/10.1177/0300060517723182">Publisher Full Text </a> | <a target=xrefwindow id=d22218e2594 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6011328">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d22218e2603 class=n-a></a>Kloppenburg M, Ramonda R, Bobacz K, <i> et al.</i>: Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(12): 1757–64. <a target=xrefwindow id=d22218e2614 href="http://www.ncbi.nlm.nih.gov/pubmed/30282670">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2617 href="https://doi.org/10.1136/annrheumdis-2018-213202">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d22218e2626 class=n-a></a>Kroon F, Bay-Jensen AC, Wittoek R, <i> et al.</i>: Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis. <i>Scand J Rheumatol.</i> 2020; <b>49</b>(2): 167–8. <a target=xrefwindow id=d22218e2637 href="http://www.ncbi.nlm.nih.gov/pubmed/31566063">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2640 href="https://doi.org/10.1080/03009742.2019.1657493">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732733793"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2649 class=n-a></a>Loef M, Kroon FPB, Bergstra SA, <i> et al.</i>: TNF inhibitor treatment is associated with a lower risk of hand osteoarthritis progression in rheumatoid arthritis patients after 10 years. <i>Rheumatology (Oxford).</i> 2018; <b>57</b>(11): 1917–24. <a target=xrefwindow id=d22218e2660 href="http://www.ncbi.nlm.nih.gov/pubmed/29471377">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2663 href="https://doi.org/10.1093/rheumatology/key016">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732733793">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d22218e2677 class=n-a></a>Lee W, Ruijgrok L, Boxma-de Klerk B, <i> et al.</i>: Efficacy of Hydroxychloroquine in Hand Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis Care Res (Hoboken).</i> 2018; <b>70</b>(9): 1320–5. <a target=xrefwindow id=d22218e2688 href="http://www.ncbi.nlm.nih.gov/pubmed/29125901">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2691 href="https://doi.org/10.1002/acr.23471">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d22218e2700 class=n-a></a>Kingsbury SR, Tharmanathan P, Keding A, <i> et al.</i>: Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis: A Randomized Trial. <i>Ann Intern Med.</i> 2018; <b>168</b>(6): 385–95. <a target=xrefwindow id=d22218e2711 href="http://www.ncbi.nlm.nih.gov/pubmed/29459986">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2714 href="https://doi.org/10.7326/M17-1430">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d22218e2723 class=n-a></a>Grothe K, Flechsenhar K, Paehler T, <i> et al.</i>: IκB kinase inhibition as a potential treatment of osteoarthritis - results of a clinical proof-of-concept study. <i>Osteoarthritis Cartilage.</i> 2017; <b>25</b>(1): 46–52. <a target=xrefwindow id=d22218e2734 href="http://www.ncbi.nlm.nih.gov/pubmed/27592041">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2737 href="https://doi.org/10.1016/j.joca.2016.08.010">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736117310"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2746 class=n-a></a>Schnitzer TJ, Easton R, Pang S, <i> et al.</i>: Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial. <i>JAMA</i> 2019; <b>322</b>(1): 37–48. <a target=xrefwindow id=d22218e2757 href="http://www.ncbi.nlm.nih.gov/pubmed/31265100">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2760 href="https://doi.org/10.1001/jama.2019.8044">Publisher Full Text </a> | <a target=xrefwindow id=d22218e2764 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6613301">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736117310">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736280654"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2777 class=n-a></a>Krupka E, Jiang GL, Jan C: Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study. <i>Osteoarthritis Cartilage.</i> 2019; <b>27</b>(11): 1599–1607. <a target=xrefwindow id=d22218e2785 href="http://www.ncbi.nlm.nih.gov/pubmed/31351965">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2788 href="https://doi.org/10.1016/j.joca.2019.05.028">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736280654">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735358902"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2801 class=n-a></a>Stevens RM, Ervin J, Nezzer J, <i> et al.</i>: Randomized, Double-Blind, Placebo-Controlled Trial of Intraarticular Trans-Capsaicin for Pain Associated With Osteoarthritis of the Knee. <i>Arthritis Rheumatol.</i> 2019; <b>71</b>(9): 1524–1533. <a target=xrefwindow id=d22218e2812 href="http://www.ncbi.nlm.nih.gov/pubmed/30888737">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2815 href="https://doi.org/10.1002/art.40894">Publisher Full Text </a> | <a target=xrefwindow id=d22218e2819 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6772016">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735358902">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d22218e2833 class=n-a></a>Mayorga AJ, Flores CM, Trudeau JJ, <i> et al.</i>: A randomized study to evaluate the analgesic efficacy of a single dose of the TRPV1 antagonist mavatrep in patients with osteoarthritis. <i>Scand J Pain.</i> 2017; <b>17</b>: 134–43. <a target=xrefwindow id=d22218e2844 href="http://www.ncbi.nlm.nih.gov/pubmed/28850367">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2847 href="https://doi.org/10.1016/j.sjpain.2017.07.021">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733312437"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2856 class=n-a></a>Manitpisitkul P, Flores CM, Moyer JA, <i> et al.</i>: A multiple-dose double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatrep). <i>Scand J Pain.</i> 2018; <b>18</b>(2): 151–64. <a target=xrefwindow id=d22218e2867 href="http://www.ncbi.nlm.nih.gov/pubmed/29794306">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2870 href="https://doi.org/10.1515/sjpain-2017-0184">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733312437">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d22218e2883 class=n-a></a>Bagal MCS, Brady P, Stauffer J: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the Hip or Knee. [abstract], ACR/ARHP Annual Meeting, Arthritis Rheumatol. 2017. <a target=xrefwindow id=d22218e2885 href="https://acrabstracts.org/abstract/a-phase-2-randomized-double-blind-placebo-controlled-titration-to-effect-study-of-orally-administered-cr845-in-patients-with-osteoarthritis-of-the-hip-or-knee/">Reference Source</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d22218e2894 class=n-a></a>Jin Y, Smith C, Monteith D, <i> et al.</i>: CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial. <i>Osteoarthritis Cartilage.</i> 2018; <b>26</b>(12): 1609–18. <a target=xrefwindow id=d22218e2905 href="http://www.ncbi.nlm.nih.gov/pubmed/30240937">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2908 href="https://doi.org/10.1016/j.joca.2018.08.019">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736628903"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2917 class=n-a></a>Rovati LC, Brambilla N, Blicharski T, <i> et al.</i>: Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial. <i>Osteoarthritis Cartilage.</i> 2020; <b>28</b>(1): 22–30. <a target=xrefwindow id=d22218e2928 href="http://www.ncbi.nlm.nih.gov/pubmed/31526875">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2931 href="https://doi.org/10.1016/j.joca.2019.09.002">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736628903">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732586809"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2944 class=n-a></a>Lu CH, Chung CH, Lee CH, <i> et al.</i>: Combination COX-2 inhibitor and metformin attenuate rate of joint replacement in osteoarthritis with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan. <i>PLoS One.</i> 2018; <b>13</b>(1): e0191242. <a target=xrefwindow id=d22218e2955 href="http://www.ncbi.nlm.nih.gov/pubmed/29385156">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2958 href="https://doi.org/10.1371/journal.pone.0191242">Publisher Full Text </a> | <a target=xrefwindow id=d22218e2962 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5791980">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732586809">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732008374"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e2976 class=n-a></a>Eymard F, Parsons C, Edwards MH, <i> et al.</i>: Statin use and knee osteoarthritis progression: Results from a post-hoc analysis of the SEKOIA trial. <i>Joint Bone Spine.</i> 2018; <b>85</b>(5): 609–14. <a target=xrefwindow id=d22218e2987 href="http://www.ncbi.nlm.nih.gov/pubmed/29037516">PubMed Abstract </a> | <a target=xrefwindow id=d22218e2990 href="https://doi.org/10.1016/j.jbspin.2017.09.014">Publisher Full Text </a> | <a target=xrefwindow id=d22218e2994 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5858762">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732008374">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733424728"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e3007 class=n-a></a>Burkard T, Hügle T, Layton JB, <i> et al.</i>: Risk of Incident Osteoarthritis of the Hand in Statin Initiators: A Sequential Cohort Study. <i>Arthritis Care Res (Hoboken).</i> 2018; <b>70</b>(12): 1795–805. <a target=xrefwindow id=d22218e3018 href="http://www.ncbi.nlm.nih.gov/pubmed/29885074">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3021 href="https://doi.org/10.1002/acr.23616">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733424728">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d22218e3034 class=n-a></a>Michaëlsson K, Lohmander LS, Turkiewicz A, <i> et al.</i>: Association Between Statin Use and Consultation or Surgery for Osteoarthritis of the Hip or Knee: A Pooled Analysis of Four Cohort Studies. <i>Osteoarthritis and Cartilage.</i> 2017; <b>25</b>(11): 1804–13. <a target=xrefwindow id=d22218e3045 href="http://www.ncbi.nlm.nih.gov/pubmed/28756279">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3048 href="https://doi.org/10.1016/j.joca.2017.07.013">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d22218e3057 class=n-a></a>Verma P, Dalal K: ADAMTS-4 and ADAMTS-5: Key enzymes in osteoarthritis. <i>J Cell Biochem.</i> 2011; <b>112</b>(12): 3507–14. <a target=xrefwindow id=d22218e3065 href="http://www.ncbi.nlm.nih.gov/pubmed/21815191">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3068 href="https://doi.org/10.1002/jcb.23298">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d22218e3077 class=n-a></a>Burrage PS, Mix KS, Brinckerhoff CE: Matrix Metalloproteinases: Role In Arthritis. <i>Front Biosci.</i> 2006; <b>11</b>: 529–43. <a target=xrefwindow id=d22218e3085 href="http://www.ncbi.nlm.nih.gov/pubmed/16146751">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3088 href="https://doi.org/10.2741/1817">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d22218e3097 class=n-a></a>Krzeski P, Buckland-Wright C, Bálint G, <i> et al.</i>: Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: A randomized, 12-month, double-blind, placebo-controlled study. <i>Arthritis Res Ther.</i> 2007; <b>9</b>(5): R109. <a target=xrefwindow id=d22218e3108 href="http://www.ncbi.nlm.nih.gov/pubmed/17958901">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3111 href="https://doi.org/10.1186/ar2315">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3115 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2212568">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d22218e3125 class=n-a></a>Roubille C, Pelletier JP, Martel-Pelletier J: New and emerging treatments for osteoarthritis management: Will the dream come true with personalized medicine? <i>Expert Opin Pharmacother.</i> 2013; <b>14</b>(15): 2059–77. <a target=xrefwindow id=d22218e3133 href="http://www.ncbi.nlm.nih.gov/pubmed/24044485">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3136 href="https://doi.org/10.1517/14656566.2013.825606">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d22218e3145 class=n-a></a>Mancuso P, Raman S, Glynn A, <i> et al.</i>: Mesenchymal Stem Cell Therapy for Osteoarthritis: The Critical Role of the Cell Secretome. <i>Front Bioeng Biotechnol.</i> 2019; <b>7</b>: 9. <a target=xrefwindow id=d22218e3156 href="http://www.ncbi.nlm.nih.gov/pubmed/30761298">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3159 href="https://doi.org/10.3389/fbioe.2019.00009">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3163 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6361779">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d22218e3172 class=n-a></a>Lee MJ, Kim J, Kim MY, <i> et al.</i>: Proteomic Analysis of Tumor Necrosis Factor-Alpha-Induced Secretome of Human Adipose Tissue-Derived Mesenchymal Stem Cells. <i>J Proteome Res.</i> 2010; <b>9</b>(4): 1754–62. <a target=xrefwindow id=d22218e3183 href="http://www.ncbi.nlm.nih.gov/pubmed/20184379">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3186 href="https://doi.org/10.1021/pr900898n">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d22218e3195 class=n-a></a>Reiner AT, Witwer KW, van Balkom BWM, <i> et al.</i>: Concise Review: Developing Best-Practice Models for the Therapeutic Use of Extracellular Vesicles. <i>Stem Cells Transl Med.</i> 2017; <b>6</b>(8): 1730–9. <a target=xrefwindow id=d22218e3206 href="http://www.ncbi.nlm.nih.gov/pubmed/28714557">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3209 href="https://doi.org/10.1002/sctm.17-0055">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3213 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5689784">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d22218e3222 class=n-a></a>Riazifar M, Pone EJ, Lötvall J, <i> et al.</i>: Stem Cell Extracellular Vesicles: Extended Messages of Regeneration. <i>Annu Rev Pharmacol Toxicol.</i> 2017; <b>57</b>: 125–54. <a target=xrefwindow id=d22218e3233 href="http://www.ncbi.nlm.nih.gov/pubmed/27814025">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3236 href="https://doi.org/10.1146/annurev-pharmtox-061616-030146">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3240 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5360275">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d22218e3249 class=n-a></a>György B, Szabó TG, Pásztói M, <i> et al.</i>: Membrane Vesicles, Current State-Of-The-Art: Emerging Role of Extracellular Vesicles. <i>Cell Mol Life Sci.</i> 2011; <b>68</b>(16): 2667–88. <a target=xrefwindow id=d22218e3260 href="http://www.ncbi.nlm.nih.gov/pubmed/21560073">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3263 href="https://doi.org/10.1007/s00018-011-0689-3">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3267 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3142546">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d22218e3277 class=n-a></a>Lässer C, Jang SC, Lötvall J: Subpopulations of Extracellular Vesicles and Their Therapeutic Potential. <i>Mol Aspects Med.</i> 2018; <b>60</b>: 1–14. <a target=xrefwindow id=d22218e3285 href="http://www.ncbi.nlm.nih.gov/pubmed/29432782">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3288 href="https://doi.org/10.1016/j.mam.2018.02.002">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d22218e3297 class=n-a></a>Malda J, Boere J, van de Lest CH, <i> et al.</i>: Extracellular Vesicles — New Tool for Joint Repair and Regeneration. <i>Nat Rev Rheumatol.</i> 2016; <b>12</b>(4): 243–9. <a target=xrefwindow id=d22218e3308 href="http://www.ncbi.nlm.nih.gov/pubmed/26729461">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3311 href="https://doi.org/10.1038/nrrheum.2015.170">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736866982"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e3320 class=n-a></a>D'Arrigo D, Roffi A, Cucchiarini M, <i> et al.</i>: Secretome and Extracellular Vesicles as New Biological Therapies for Knee Osteoarthritis: A Systematic Review. <i>J Clin Med.</i> 2019; <b>8</b>(11): 1867 . <a target=xrefwindow id=d22218e3331 href="http://www.ncbi.nlm.nih.gov/pubmed/31689923">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3334 href="https://doi.org/10.3390/jcm8111867">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3338 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6912212">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736866982">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735423138"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e3351 class=n-a></a>Wu J, Kuang L, Chen C, <i> et al.</i>: miR-100-5p-abundant Exosomes Derived From Infrapatellar Fat Pad MSCs Protect Articular Cartilage and Ameliorate Gait Abnormalities via Inhibition of mTOR in Osteoarthritis. <i>Biomaterials.</i> 2019; <b>206</b>: 87–100. <a target=xrefwindow id=d22218e3362 href="http://www.ncbi.nlm.nih.gov/pubmed/30927715">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3365 href="https://doi.org/10.1016/j.biomaterials.2019.03.022">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735423138">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734377656"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e3378 class=n-a></a>Khatab S, van Osch GJ, Kops N, <i> et al.</i>: Mesenchymal Stem Cell Secretome Reduces Pain and Prevents Cartilage Damage in a Murine Osteoarthritis Model. <i>Eur Cell Mater.</i> 2018; <b>36</b>: 218–30. <a target=xrefwindow id=d22218e3389 href="http://www.ncbi.nlm.nih.gov/pubmed/30398288">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3392 href="https://doi.org/10.22203/eCM.v036a16">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734377656">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d22218e3405 class=n-a></a>Malekipour F, Whitton C, Oetomo D, <i> et al.</i>: Shock Absorbing Ability of Articular Cartilage and Subchondral Bone Under Impact Compression. <i>J Mech Behav Biomed Mater.</i> 2013; <b>26</b>: 127–35. <a target=xrefwindow id=d22218e3416 href="http://www.ncbi.nlm.nih.gov/pubmed/23746699">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3419 href="https://doi.org/10.1016/j.jmbbm.2013.05.005">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d22218e3429 class=n-a></a>Li G, Yin J, Gao J, <i> et al.</i>: Subchondral bone in osteoarthritis: insight into risk factors and microstructural changes. <i>Arthritis Res Ther.</i> 2013; <b>15</b>(6): 223. <a target=xrefwindow id=d22218e3440 href="http://www.ncbi.nlm.nih.gov/pubmed/24321104">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3443 href="https://doi.org/10.1186/ar4405">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3447 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4061721">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d22218e3456 class=n-a></a>Buckland-Wright C: Subchondral bone changes in hand and knee osteoarthritis detected by radiography. <i>Osteoarthritis Cartilage.</i> 2004; <b>12</b>(Suppl A):S10–9. <a target=xrefwindow id=d22218e3464 href="http://www.ncbi.nlm.nih.gov/pubmed/14698636">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3467 href="https://doi.org/10.1016/j.joca.2003.09.007">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d22218e3476 class=n-a></a>Burr DB, Gallant MA: Bone remodelling in osteoarthritis. <i>Nat Rev Rheumatol.</i> 2012; <b>8</b>(11): 665–73. <a target=xrefwindow id=d22218e3484 href="http://www.ncbi.nlm.nih.gov/pubmed/22868925">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3487 href="https://doi.org/10.1038/nrrheum.2012.130">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732338309"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e3496 class=n-a></a>Alliston T, Hernandez CJ, Findlay DM, <i> et al.</i>: Bone marrow lesions in osteoarthritis: What lies beneath. <i>J Orthop Res.</i> 2018; <b>36</b>(7): 1818–25. <a target=xrefwindow id=d22218e3507 href="http://www.ncbi.nlm.nih.gov/pubmed/29266428">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3510 href="https://doi.org/10.1002/jor.23844">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732338309">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d22218e3523 class=n-a></a>Deveza LA, Bierma-Zeinstra SMA, van Spil WE, <i> et al.</i>: Efficacy of bisphosphonates in specific knee osteoarthritis subpopulations: protocol for an OA Trial Bank systematic review and individual patient data meta-analysis. <i>BMJ Open.</i> 2018; <b>8</b>(12): e023889. <a target=xrefwindow id=d22218e3534 href="http://www.ncbi.nlm.nih.gov/pubmed/30573485">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3537 href="https://doi.org/10.1136/bmjopen-2018-023889">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3541 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6303587">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734614694"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e3550 class=n-a></a>Zhu S, Zhu J, Zhen G, <i> et al.</i>: Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. <i>J Clin Invest.</i> 2019; <b>129</b>(3): 1076–93. <a target=xrefwindow id=d22218e3561 href="http://www.ncbi.nlm.nih.gov/pubmed/30530994">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3564 href="https://doi.org/10.1172/JCI121561">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3568 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6391093">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734614694">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732824430"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e3582 class=n-a></a>Lindström E, Rizoska B, Tunblad K, <i> et al.</i>: The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis. <i>J Transl Med.</i> 2018; <b>16</b>(1): 56. <a target=xrefwindow id=d22218e3593 href="http://www.ncbi.nlm.nih.gov/pubmed/29523155">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3596 href="https://doi.org/10.1186/s12967-018-1425-7">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3600 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5845353">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732824430">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d22218e3613 class=n-a></a>van der Kraan PM: Differential Role of Transforming Growth Factor-beta in an Osteoarthritic or a Healthy Joint. <i>J Bone Metab.</i> 2018; <b>25</b>(2): 65–72. <a target=xrefwindow id=d22218e3621 href="http://www.ncbi.nlm.nih.gov/pubmed/29900155">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3624 href="https://doi.org/10.11005/jbm.2018.25.2.65">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3627 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5995759">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d22218e3636 class=n-a></a>Xie L, Tintani F, Wang X, <i> et al.</i>: Systemic neutralization of TGF-β attenuates osteoarthritis. <i>Ann N Y Acad Sci.</i> 2016; <b>1376</b>(1): 53–64. <a target=xrefwindow id=d22218e3647 href="http://www.ncbi.nlm.nih.gov/pubmed/26837060">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3650 href="https://doi.org/10.1111/nyas.13000">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3654 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4970979">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732543007"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e3663 class=n-a></a>Chen CH, Ho ML, Chang LH, <i> et al.</i>: Parathyroid hormone-(1-34) ameliorated knee osteoarthritis in rats via autophagy. <i>J Appl Physiol.</i> 2018; <b>124</b>(5): 1177–85. <a target=xrefwindow id=d22218e3674 href="http://www.ncbi.nlm.nih.gov/pubmed/29357491">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3677 href="https://doi.org/10.1152/japplphysiol.00871.2017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732543007">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d22218e3690 class=n-a></a>Bikle DD: Vitamin D and Bone. <i>Curr Osteoporos Rep.</i> 2012; <b>10</b>(2): 151–9. <a target=xrefwindow id=d22218e3698 href="http://www.ncbi.nlm.nih.gov/pubmed/22544628">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3701 href="https://doi.org/10.1007/s11914-012-0098-z">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3704 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3688475">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d22218e3713 class=n-a></a>Yu Y, Liu D, Feng D, <i> et al.</i>: Association between Vitamin D and Knee Osteoarthritis: A PRISMA-Compliant Meta-analysis. <i>Z Orthop Unfall.</i> 2020. <a target=xrefwindow id=d22218e3721 href="http://www.ncbi.nlm.nih.gov/pubmed/32150754">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3724 href="https://doi.org/10.1055/a-1098-8815">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d22218e3734 class=n-a></a>Gao XR, Chen YS, Deng W: The effect of vitamin D supplementation on knee osteoarthritis: A meta-analysis of randomized controlled trials. <i>Int J Surg.</i> 2017; <b>46</b>: 14–20. <a target=xrefwindow id=d22218e3742 href="http://www.ncbi.nlm.nih.gov/pubmed/28797917">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3745 href="https://doi.org/10.1016/j.ijsu.2017.08.010">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d22218e3754 class=n-a></a>Sizar O, Khare S, Goyal A, <i> et al.</i>: Vitamin D Deficiency. StatPearls, StatPearls Publishing, StatPearls Publishing LLC., Treasure Island (FL). 2020. <a target=xrefwindow id=d22218e3759 href="http://www.ncbi.nlm.nih.gov/pubmed/30335299">PubMed Abstract </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718216024"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e3768 class=n-a></a>Berenbaum F: Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). <i>Osteoarthritis Cartilage.</i> 2013; <b>21</b>(1): 16–21. <a target=xrefwindow id=d22218e3776 href="http://www.ncbi.nlm.nih.gov/pubmed/23194896">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3779 href="https://doi.org/10.1016/j.joca.2012.11.012">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718216024">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727262014"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e3792 class=n-a></a>Mathiessen A, Conaghan PG: Synovitis in osteoarthritis: Current understanding with therapeutic implications. <i>Arthritis Res Ther.</i> 2017; <b>19</b>(1): 18. <a target=xrefwindow id=d22218e3800 href="https://doi.org/10.1186/s13075-017-1229-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727262014">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d22218e3813 class=n-a></a>Hayashi D, Roemer FW, Katur A, <i> et al.</i>: Imaging of synovitis in osteoarthritis: current status and outlook. <i>Semin Arthritis Rheum.</i> 2011; <b>41</b>(2): 116–30. <a target=xrefwindow id=d22218e3824 href="http://www.ncbi.nlm.nih.gov/pubmed/21295331">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3827 href="https://doi.org/10.1016/j.semarthrit.2010.12.003">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d22218e3836 class=n-a></a>Millerand M, Berenbaum F, Jacques C: Danger signals and inflammaging in osteoarthritis. <i>Clin Exp Rheumatol.</i> 2019; <b>37</b>(Suppl 120): 48–56. <a target=xrefwindow id=d22218e3844 href="http://www.ncbi.nlm.nih.gov/pubmed/31621566">PubMed Abstract </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736520831"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e3854 class=n-a></a>Woodell-May JE, Sommerfeld SD: Role of Inflammation and the Immune System in the Progression of Osteoarthritis. <i>J Orthop Res.</i> 2020; <b>38</b>(2): 253–7. <a target=xrefwindow id=d22218e3862 href="http://www.ncbi.nlm.nih.gov/pubmed/31469192">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3865 href="https://doi.org/10.1002/jor.24457">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736520831">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d22218e3878 class=n-a></a>Pelletier JP, Martel-Pelletier J, Rannou F, <i> et al.</i>: Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys. <i>Semin Arthritis Rheum.</i> 2016; <b>45</b>(4 Suppl): S22–S27. <a target=xrefwindow id=d22218e3889 href="http://www.ncbi.nlm.nih.gov/pubmed/26806184">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3892 href="https://doi.org/10.1016/j.semarthrit.2015.11.009">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d22218e3901 class=n-a></a>Savvidou O, Milonaki M, Goumenos S, <i> et al.</i>: Glucocorticoid signaling and osteoarthritis. <i>Mol Cell Endocrinol.</i> 2019; <b>480</b>: 153–66. <a target=xrefwindow id=d22218e3912 href="http://www.ncbi.nlm.nih.gov/pubmed/30445185">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3915 href="https://doi.org/10.1016/j.mce.2018.11.001">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d22218e3924 class=n-a></a>Cook AD, Pobjoy J, Steidl S, <i> et al.</i>: Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. <i>Arthritis Res Ther.</i> 2012; <b>14</b>(5): R199. <a target=xrefwindow id=d22218e3935 href="http://www.ncbi.nlm.nih.gov/pubmed/22995428">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3938 href="https://doi.org/10.1186/ar4037">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3942 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3580511">Free Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736727951"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e3951 class=n-a></a>Grieshaber-Bouyer R, Kämmerer T, Rosshirt N, <i> et al.</i>: Divergent Mononuclear Cell Participation and Cytokine Release Profiles Define Hip and Knee Osteoarthritis. <i>J Clin Med.</i> 2019; <b>8</b>(10). pii: E1631 <a target=xrefwindow id=d22218e3962 href="http://www.ncbi.nlm.nih.gov/pubmed/31590365">PubMed Abstract </a> | <a target=xrefwindow id=d22218e3965 href="https://doi.org/10.3390/jcm8101631">Publisher Full Text </a> | <a target=xrefwindow id=d22218e3969 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6832735">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736727951">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d22218e3982 class=n-a></a>Schett G, Bainbridge C, Berkowitz M, <i> et al.</i>: A Phase IIa Study of Anti-GM-CSF Antibody GSK3196165 in Subjects with Inflammatory Hand Osteoarthritis. 2018. ACR/ARHP Annual Meeting, 2018. <a target=xrefwindow id=d22218e3987 href="https://acrabstracts.org/abstract/a-phase-iia-study-of-anti-gm-csf-antibody-gsk3196165-in-subjects-with-inflammatory-hand-osteoarthritis/">Reference Source</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d22218e3997 class=n-a></a>Crotti C, Biggioggero M, Becciolini A, <i> et al.</i>: Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. <i>Expert Opin Investig Drugs.</i> 2019; <b>28</b>(7): 573–81. <a target=xrefwindow id=d22218e4008 href="http://www.ncbi.nlm.nih.gov/pubmed/31208237">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4011 href="https://doi.org/10.1080/13543784.2019.1631795">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d22218e4020 class=n-a></a>Sun S, Rao NL, Venable J, <i> et al.</i>: TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. <i>Inflamm Allergy Drug Targets.</i> 2007; <b>6</b>(4): 223–35. <a target=xrefwindow id=d22218e4031 href="http://www.ncbi.nlm.nih.gov/pubmed/18220957">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4034 href="https://doi.org/10.2174/187152807783334300">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d22218e4043 class=n-a></a>Kawasaki T, Kawai T: Toll-like receptor signaling pathways. <i>Front Immunol.</i> 2014; <b>5</b>: 461. <a target=xrefwindow id=d22218e4051 href="http://www.ncbi.nlm.nih.gov/pubmed/25309543">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4054 href="https://doi.org/10.3389/fimmu.2014.00461">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4057 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4174766">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732824287"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e4066 class=n-a></a>Maudens P, Seemayer CA, Pfefferlé F, <i> et al.</i>: Nanocrystals of a potent p38 MAPK inhibitor embedded in microparticles: Therapeutic effects in inflammatory and mechanistic murine models of osteoarthritis. <i>J Control Release.</i> 2018; <b>276</b>: 102–12. <a target=xrefwindow id=d22218e4077 href="http://www.ncbi.nlm.nih.gov/pubmed/29524442">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4080 href="https://doi.org/10.1016/j.jconrel.2018.03.007">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732824287">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737100043"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e4093 class=n-a></a>Hoshikawa N, Sakai A, Takai S, <i> et al.</i>: Targeting Extracellular miR-21-TLR7 Signaling Provides Long-Lasting Analgesia in Osteoarthritis. <i>Mol Ther Nucleic Acids.</i> 2020; <b>19</b>: 199–207. <a target=xrefwindow id=d22218e4104 href="http://www.ncbi.nlm.nih.gov/pubmed/31841992">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4107 href="https://doi.org/10.1016/j.omtn.2019.11.011">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4111 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6920297">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737100043">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726822616"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e4124 class=n-a></a>Struglics A, Okroj M, Swärd P, <i> et al.</i>: The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis. <i>Arthritis Res Ther.</i> 2016; <b>18</b>(1): 223. <a target=xrefwindow id=d22218e4135 href="http://www.ncbi.nlm.nih.gov/pubmed/27716448">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4138 href="https://doi.org/10.1186/s13075-016-1123-x">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4142 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5052889">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726822616">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13387960"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e4156 class=n-a></a>Wang Q, Rozelle AL, Lepus CM, <i> et al.</i>: Identification of a central role for complement in osteoarthritis. <i>Nat Med.</i> 2011; <b>17</b>(12): 1674–9. <a target=xrefwindow id=d22218e4167 href="http://www.ncbi.nlm.nih.gov/pubmed/22057346">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4170 href="https://doi.org/10.1038/nm.2543">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4174 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3257059">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13387960">F1000 Recommendation</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d22218e4187 class=n-a></a>Ricklin D, Mastellos DC, Lambris JD: Therapeutic targeting of the complement system. <i>Nat Rev Drug Discov.</i> 2019. <a target=xrefwindow id=d22218e4192 href="http://www.ncbi.nlm.nih.gov/pubmed/31819218">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4195 href="https://doi.org/10.1038/s41573-019-0055-y">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736797567"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e4204 class=n-a></a>Zhu W, Zhang X, Jiang Y, <i> et al.</i>: Alterations in peripheral T cell and B cell subsets in patients with osteoarthritis. <i>Clin Rheumatol.</i> 2020; <b>39</b>(2): 523–32. <a target=xrefwindow id=d22218e4215 href="http://www.ncbi.nlm.nih.gov/pubmed/31624962">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4218 href="https://doi.org/10.1007/s10067-019-04768-y">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736797567">F1000 Recommendation</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734307291"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e4231 class=n-a></a>Rosshirt N, Hagmann S, Tripel E, <i> et al.</i>: A predominant Th1 polarization is present in synovial fluid of end-stage osteoarthritic knee joints: analysis of peripheral blood, synovial fluid and synovial membrane. <i>Clin Exp Immunol.</i> 2019; <b>195</b>(3): 395–406. <a target=xrefwindow id=d22218e4242 href="http://www.ncbi.nlm.nih.gov/pubmed/30368774">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4245 href="https://doi.org/10.1111/cei.13230">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4249 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6378378">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734307291">F1000 Recommendation</a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d22218e4262 class=n-a></a>Her M, Kavanaugh A: Alterations in immune function with biologic therapies for autoimmune disease. <i>J Allergy Clin Immunol.</i> 2016; <b>137</b>(1): 19–27. <a target=xrefwindow id=d22218e4270 href="http://www.ncbi.nlm.nih.gov/pubmed/26768759">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4273 href="https://doi.org/10.1016/j.jaci.2015.10.023">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d22218e4282 class=n-a></a>Madry H, Cucchiarini M: Gene therapy for human osteoarthritis: principles and clinical translation. <i>Expert Opin Biol Ther.</i> 2016; <b>16</b>(3): 331–46. <a target=xrefwindow id=d22218e4290 href="http://www.ncbi.nlm.nih.gov/pubmed/26593049">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4293 href="https://doi.org/10.1517/14712598.2016.1124084">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737756855"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e4303 class=n-a></a>Watson Levings RS, Broome TA, Smith AD, <i> et al.</i>: Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model. <i>Hum Gene Ther Clin Dev.</i> 2018; <b>29</b>(2): 90–100. <a target=xrefwindow id=d22218e4314 href="http://www.ncbi.nlm.nih.gov/pubmed/29869540">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4317 href="https://doi.org/10.1089/humc.2017.142">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4321 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6007808">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737756855">F1000 Recommendation</a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d22218e4334 class=n-a></a>Fu K, Robbins SR, McDougall JJ: Osteoarthritis: the genesis of pain. <i>Rheumatology (Oxford).</i> 2018; <b>57</b>(suppl_4): iv43–iv50. <a target=xrefwindow id=d22218e4342 href="http://www.ncbi.nlm.nih.gov/pubmed/29267879">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4345 href="https://doi.org/10.1093/rheumatology/kex419">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d22218e4354 class=n-a></a>Trouvin AP, Perrot S: Pain in osteoarthritis. Implications for optimal management. <i>Joint Bone Spine.</i> 2018; <b>85</b>(4): 429–34. <a target=xrefwindow id=d22218e4362 href="http://www.ncbi.nlm.nih.gov/pubmed/28889010">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4365 href="https://doi.org/10.1016/j.jbspin.2017.08.002">Publisher Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d22218e4374 class=n-a></a>Neogi T: Structural correlates of pain in osteoarthritis. <i>Clin Exp Rheumatol.</i> 2017; <b>35 Suppl 107</b>(5): 75–8. <a target=xrefwindow id=d22218e4382 href="http://www.ncbi.nlm.nih.gov/pubmed/28967355">PubMed Abstract </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d22218e4391 class=n-a></a>Mesci N, Mesci E, Külcü DG: Association of neuropathic pain with ultrasonographic measurements of femoral cartilage thickness and clinical parameters in patients with knee osteoarthritis. <i>J Phys Ther Sci.</i> 2016; <b>28</b>(8): 2190–5. <a target=xrefwindow id=d22218e4399 href="http://www.ncbi.nlm.nih.gov/pubmed/27630395">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4402 href="https://doi.org/10.1589/jpts.28.2190">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4405 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5011559">Free Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736671650"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e4414 class=n-a></a>Stapledon CJ, Tsangari H, Solomon LB, <i> et al.</i>: Human osteocyte expression of Nerve Growth Factor: The effect of Pentosan Polysulphate Sodium (PPS) and implications for pain associated with knee osteoarthritis. <i>PLoS One.</i> 2019; <b>14</b>(9): e0222602. <a target=xrefwindow id=d22218e4425 href="http://www.ncbi.nlm.nih.gov/pubmed/31557169">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4428 href="https://doi.org/10.1371/journal.pone.0222602">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4432 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6762051">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736671650">F1000 Recommendation</a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d22218e4446 class=n-a></a>Pecchi E, Priam S, Gosset M, <i> et al.</i>: Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain. <i>Arthritis Res Ther.</i> 2014; <b>16</b>(1): R16. <a target=xrefwindow id=d22218e4457 href="http://www.ncbi.nlm.nih.gov/pubmed/24438745">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4460 href="https://doi.org/10.1186/ar4443">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4464 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3978639">Free Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d22218e4473 class=n-a></a>Takano S, Uchida K, Miyagi M, <i> et al.</i>: Nerve Growth Factor Regulation by TNF-α and IL-1β in Synovial Macrophages and Fibroblasts in Osteoarthritic Mice. <i>J Immunol Res.</i> 2016; <b>2016</b>(11): 1–8. <a target=xrefwindow id=d22218e4484 href="http://www.ncbi.nlm.nih.gov/pubmed/27635406">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4487 href="https://doi.org/10.1155/2016/5706359">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4491 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5007361">Free Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734690148"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e4500 class=n-a></a>Sakurai Y, Fujita M, Kawasaki S, <i> et al.</i>: Contribution of synovial macrophages to rat advanced osteoarthritis pain resistant to cyclooxygenase inhibitors. <i>Pain.</i> 2019; <b>160</b>(4): 895–907. <a target=xrefwindow id=d22218e4511 href="http://www.ncbi.nlm.nih.gov/pubmed/30585984">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4514 href="https://doi.org/10.1097/j.pain.0000000000001466">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734690148">F1000 Recommendation</a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d22218e4527 class=n-a></a>Aso K, Shahtaheri SM, Hill R, <i> et al.</i>: Associations of Symptomatic Knee Osteoarthritis With Histopathologic Features in Subchondral Bone. <i>Arthritis Rheumatol.</i> 2019; <b>71</b>(6): 916–24. <a target=xrefwindow id=d22218e4538 href="http://www.ncbi.nlm.nih.gov/pubmed/30663865">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4541 href="https://doi.org/10.1002/art.40820">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d22218e4550 class=n-a></a>Miller RE, Malfait AM, Block JA: Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. <i>Clin Exp Rheumatol.</i> 2017; <b>35 Suppl 107</b>(5): 85–7. <a target=xrefwindow id=d22218e4558 href="http://www.ncbi.nlm.nih.gov/pubmed/28967370">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4561 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6007861">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d22218e4570 class=n-a></a>Schmelz M, Mantyh P, Malfait AM, <i> et al.</i>: Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety <i>Pain.</i> 2019; <b>160</b>(10): 2210–20. <a target=xrefwindow id=d22218e4581 href="http://www.ncbi.nlm.nih.gov/pubmed/31145219">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4584 href="https://doi.org/10.1097/j.pain.0000000000001625">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4588 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6756297">Free Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735320368"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e4598 class=n-a></a>von Loga IS, El-Turabi A, Jostins L, <i> et al.</i>: Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis. <i>Ann Rheum Dis.</i> 2019; <b>78</b>(5): 672–5. <a target=xrefwindow id=d22218e4609 href="http://www.ncbi.nlm.nih.gov/pubmed/30862648">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4612 href="https://doi.org/10.1136/annrheumdis-2018-214489">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4616 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6517802">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735320368">F1000 Recommendation</a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d22218e4629 class=n-a></a>Nwosu LN, Mapp PI, Chapman V, <i> et al.</i>: Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis. <i>Ann Rheum Dis.</i> 2016; <b>75</b>(6): 1246–54. <a target=xrefwindow id=d22218e4640 href="http://www.ncbi.nlm.nih.gov/pubmed/26286016">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4643 href="https://doi.org/10.1136/annrheumdis-2014-207203">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4647 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4893148">Free Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d22218e4656 class=n-a></a>Ashraf S, Bouhana KS, Pheneger J, <i> et al.</i>: Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis. <i>Arthritis Res Ther.</i> 2016; <b>18</b>(1): 97. <a target=xrefwindow id=d22218e4667 href="http://www.ncbi.nlm.nih.gov/pubmed/27145816">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4670 href="https://doi.org/10.1186/s13075-016-0996-z">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4674 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4857260">Free Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d22218e4683 class=n-a></a>Watt FE, Blauwet MB, Fakhoury A, <i> et al.</i>: Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial. <i>Osteoarthritis Cartilage.</i> 2019; <b>27</b>(11): 1590–1598. <a target=xrefwindow id=d22218e4694 href="http://www.ncbi.nlm.nih.gov/pubmed/31356878">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4697 href="https://doi.org/10.1016/j.joca.2019.05.029">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d22218e4706 class=n-a></a>Montagnoli C, Tiribuzi R, Crispoltoni L, <i> et al.</i>: β-NGF and β-NGF receptor upregulation in blood and synovial fluid in osteoarthritis. <i>Biol Chem.</i> 2017; <b>398</b>(9): 1045–1054. <a target=xrefwindow id=d22218e4717 href="http://www.ncbi.nlm.nih.gov/pubmed/28253191">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4720 href="https://doi.org/10.1515/hsz-2016-0280">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d22218e4729 class=n-a></a>Iwakura N, Ohtori S, Orita S, <i> et al.</i>: Role of low-affinity nerve growth factor receptor inhibitory antibody in reducing pain behavior and calcitonin gene-related Peptide expression in a rat model of wrist joint inflammatory pain. <i>J Hand Surg Am.</i> 2010; <b>35</b>(2): 267–73. <a target=xrefwindow id=d22218e4740 href="http://www.ncbi.nlm.nih.gov/pubmed/20060234">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4743 href="https://doi.org/10.1016/j.jhsa.2009.10.030">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d22218e4753 class=n-a></a>Galindo T, Reyna J, Weyer A: Evidence for Transient Receptor Potential (TRP) Channel Contribution to Arthritis Pain and Pathogenesis. <i>Pharmaceuticals (Basel).</i> 2018; <b>11</b>(4). pii: E105. <a target=xrefwindow id=d22218e4761 href="http://www.ncbi.nlm.nih.gov/pubmed/30326593">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4764 href="https://doi.org/10.3390/ph11040105">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4767 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6315622">Free Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d22218e4776 class=n-a></a>Rahman W, Dickenson AH: Osteoarthritis-dependent changes in antinociceptive action of Na<sub>v</sub>1.7 and Na<sub>v</sub>1.8 sodium channel blockers: An <i>in vivo</i> electrophysiological study in the rat. <i>Neuroscience.</i> 2015; <b>295</b>: 103–16. <a target=xrefwindow id=d22218e4794 href="http://www.ncbi.nlm.nih.gov/pubmed/25818052">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4797 href="https://doi.org/10.1016/j.neuroscience.2015.03.042">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4800 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4414363">Free Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d22218e4809 class=n-a></a>Manitpisitkul P, Mayorga A, Shalayda K, <i> et al.</i>: Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Learnings from a Double-Blind, Randomized, Placebo-Controlled, Sequential Group First-in-Human Study of the TRPV1 Antagonist, JNJ-38893777, in Healthy Men. <i>Clin Drug Investig.</i> 2015; <b>35</b>(6): 353–63. <a target=xrefwindow id=d22218e4820 href="http://www.ncbi.nlm.nih.gov/pubmed/25894894">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4823 href="https://doi.org/10.1007/s40261-015-0285-7">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d22218e4832 class=n-a></a>Lee J, Kim BH, Yu KS, <i> et al.</i>: A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers. <i>Drug Des Devel Ther.</i> 2017; <b>11</b>: 1301–1313. <a target=xrefwindow id=d22218e4843 href="http://www.ncbi.nlm.nih.gov/pubmed/28479852">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4846 href="https://doi.org/10.2147/DDDT.S128727">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4850 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5411174">Free Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d22218e4859 class=n-a></a>Miller F, Björnsson M, Svensson O, <i> et al.</i>: Experiences with an adaptive design for a dose-finding study in patients with osteoarthritis. <i>Contemp Clin Trials.</i> 2014; <b>37</b>(2): 189–99. <a target=xrefwindow id=d22218e4870 href="http://www.ncbi.nlm.nih.gov/pubmed/24394343">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4873 href="https://doi.org/10.1016/j.cct.2013.12.007">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d22218e4882 class=n-a></a>Arsenault P, Chiche D, Brown W, <i> et al.</i>: NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain. <i>Pain Rep.</i> 2018; <b>3</b>(6): e696. <a target=xrefwindow id=d22218e4893 href="http://www.ncbi.nlm.nih.gov/pubmed/30706039">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4896 href="https://doi.org/10.1097/PR9.0000000000000696">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4900 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6344137">Free Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d22218e4910 class=n-a></a>Hameed S: Na<sub>v</sub>1.7 and Na<sub>v</sub>1.8: Role in the pathophysiology of pain. <i>Mol Pain.</i> 2019; <b>15</b>: 1744806919858801. <a target=xrefwindow id=d22218e4924 href="http://www.ncbi.nlm.nih.gov/pubmed/31172839">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4928 href="https://doi.org/10.1177/1744806919858801">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4931 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6589956">Free Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d22218e4940 class=n-a></a>Schuelert N, McDougall JJ: Involvement of Nav 1.8 sodium ion channels in the transduction of mechanical pain in a rodent model of osteoarthritis. <i>Arthritis Res Ther.</i> 2012; <b>14</b>(1): R5. <a target=xrefwindow id=d22218e4948 href="http://www.ncbi.nlm.nih.gov/pubmed/22225591">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4951 href="https://doi.org/10.1186/ar3553">Publisher Full Text </a> | <a target=xrefwindow id=d22218e4954 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3392791">Free Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d22218e4963 class=n-a></a>Vertex, Third Positive Phase 2 Proof-of-Concept Study for VX-150 Further Validates the Potential Role of NaV1.8 Inhibition. 2018. <a target=xrefwindow id=d22218e4965 href="https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-phase-2-data-third-proof-concept-study">Reference Source</a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d22218e4974 class=n-a></a>Mustazza C, Pieretti S, Marzoli F: Nociceptin /Orphanin FQ Peptide (NOP) Receptor Modulators: An Update in Structure-Activity Relationships. <i>Curr Med Chem.</i> 2018; <b>25</b>(20): 2353–84. <a target=xrefwindow id=d22218e4982 href="http://www.ncbi.nlm.nih.gov/pubmed/29332567">PubMed Abstract </a> | <a target=xrefwindow id=d22218e4985 href="https://doi.org/10.2174/0929867325666180111095458">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727742179"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e4994 class=n-a></a>Christoph A, Eerdekens MH, Kok M, <i> et al.</i>: Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. <i>Pain.</i> 2017; <b>158</b>(9): 1813–24. <a target=xrefwindow id=d22218e5005 href="http://www.ncbi.nlm.nih.gov/pubmed/28644196">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5008 href="https://doi.org/10.1097/j.pain.0000000000000986">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5012 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5761752">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727742179">F1000 Recommendation</a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736504237"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e5025 class=n-a></a>Vellani V, Sabatini C, Milia C, <i> et al.</i>: CR4056, a powerful analgesic imidazoline-2 receptor ligand, inhibits the inflammation-induced PKCε phosphorylation and membrane translocation in sensory neurons. <i>Br J Pharmacol.</i> 2019; <b>177</b>(1): 48–64. <a target=xrefwindow id=d22218e5036 href="http://www.ncbi.nlm.nih.gov/pubmed/31454418">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5039 href="https://doi.org/10.1111/bph.14845">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5043 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6976787">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736504237">F1000 Recommendation</a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d22218e5057 class=n-a></a>Comi E, Lanza M, Ferrari F, <i> et al.</i>: Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis. <i>J Pain Res.</i> 2017; <b>10</b>: 1033–43. <a target=xrefwindow id=d22218e5068 href="http://www.ncbi.nlm.nih.gov/pubmed/28496359">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5071 href="https://doi.org/10.2147/JPR.S132026">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5075 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5422496">Free Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d22218e5084 class=n-a></a>Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. <i>Lancet.</i> 2005; <b>365</b>(9468): 1415–28. <a target=xrefwindow id=d22218e5092 href="http://www.ncbi.nlm.nih.gov/pubmed/15836891">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5095 href="https://doi.org/10.1016/S0140-6736(05)66378-7">Publisher Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d22218e5104 class=n-a></a>Yusuf E, Nelissen RG, Ioan-Facsinay A, <i> et al.</i>: Association between weight or body mass index and hand osteoarthritis: a systematic review. <i>Ann Rheum Dis.</i> 2010; <b>69</b>(4): 761–5. <a target=xrefwindow id=d22218e5115 href="http://www.ncbi.nlm.nih.gov/pubmed/19487215">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5118 href="https://doi.org/10.1136/ard.2008.106930">Publisher Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d22218e5127 class=n-a></a>Niu J, Clancy M, Aliabadi P, <i> et al.</i>: Metabolic Syndrome, Its Components, and Knee Osteoarthritis: The Framingham Osteoarthritis Study. <i>Arthritis Rheumatol.</i> 2017; <b>69</b>(6): 1194–203. <a target=xrefwindow id=d22218e5138 href="http://www.ncbi.nlm.nih.gov/pubmed/28257604">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5141 href="https://doi.org/10.1002/art.40087">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5145 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5449217">Free Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d22218e5154 class=n-a></a>Veronese N, Cooper C, Reginster JY: Type 2 Diabetes Mellitus and Osteoarthritis. <i>Semin Arthritis Rheum.</i> 2019; <b>49</b>(1): 9–19. <a target=xrefwindow id=d22218e5162 href="http://www.ncbi.nlm.nih.gov/pubmed/30712918">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5165 href="https://doi.org/10.1016/j.semarthrit.2019.01.005">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5168 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6642878">Free Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d22218e5177 class=n-a></a>Courties A, Gualillo O, Berenbaum F, <i> et al.</i>: Metabolic stress-induced joint inflammation and osteoarthritis. <i>Osteoarthritis Cartilage.</i> 2015; <b>23</b>(11): 1955–65. <a target=xrefwindow id=d22218e5188 href="http://www.ncbi.nlm.nih.gov/pubmed/26033164">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5191 href="https://doi.org/10.1016/j.joca.2015.05.016">Publisher Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d22218e5201 class=n-a></a>Lotz M, Caramés B: Autophagy: a new therapeutic target in cartilage injury and osteoarthritis. <i>J Am Acad Orthop Surg.</i> 2012; <b>20</b>(4): 261–2. <a target=xrefwindow id=d22218e5209 href="http://www.ncbi.nlm.nih.gov/pubmed/22474097">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5212 href="https://doi.org/10.5435/JAAOS-20-04-261">Publisher Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d22218e5221 class=n-a></a>Husa M, Petursson F, Lotz M, <i> et al.</i>: C/EBP homologous protein drives pro-catabolic responses in chondrocytes. <i>Arthritis Res Ther.</i> 2013; <b>15</b>(6): R218. <a target=xrefwindow id=d22218e5232 href="http://www.ncbi.nlm.nih.gov/pubmed/24351550">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5235 href="https://doi.org/10.1186/ar4415">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5239 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3978428">Free Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d22218e5248 class=n-a></a>Mobasheri A, Rayman MP, Gualillo O, <i> et al.</i>: The role of metabolism in the pathogenesis of osteoarthritis. <i>Nat Rev Rheumatol.</i> 2017; <b>13</b>(5): 302–11. <a target=xrefwindow id=d22218e5259 href="http://www.ncbi.nlm.nih.gov/pubmed/28381830">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5262 href="https://doi.org/10.1038/nrrheum.2017.50">Publisher Full Text </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d22218e5271 class=n-a></a>Farnaghi S, Prasadam I, Cai G, <i> et al.</i>: Statin use and knee osteoarthritis progression: Results from a post-hoc analysis of the SEKOIA trial. <i>FASEB J.</i> 2017; <b>31</b>(1): 356–67. <a target=xrefwindow id=d22218e5282 href="http://www.ncbi.nlm.nih.gov/pubmed/27737897">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5285 href="https://doi.org/10.1096/fj.201600600R">Publisher Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d22218e5294 class=n-a></a>Loeser RF: Aging processes and the development of osteoarthritis. <i>Curr Opin Rheumatol.</i> 2013; <b>25</b>(1): 108–13. <a target=xrefwindow id=d22218e5302 href="http://www.ncbi.nlm.nih.gov/pubmed/23080227">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5305 href="https://doi.org/10.1097/BOR.0b013e32835a9428">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5308 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3713615">Free Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d22218e5317 class=n-a></a>Loeser RF, Collins JA, Diekman BO: Ageing and the pathogenesis of osteoarthritis. <i>Nat Rev Rheumatol.</i> 2016; <b>12</b>(7): 412–20. <a target=xrefwindow id=d22218e5325 href="http://www.ncbi.nlm.nih.gov/pubmed/27192932">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5328 href="https://doi.org/10.1038/nrrheum.2016.65">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5331 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4938009">Free Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d22218e5341 class=n-a></a>Loeser RF: The Role of Aging in the Development of Osteoarthritis. <i>Trans Am Clin Climatol Assoc.</i> 2017; <b>128</b>: 44–54. <a target=xrefwindow id=d22218e5349 href="http://www.ncbi.nlm.nih.gov/pubmed/28790486">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5352 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5525396">Free Full Text </a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d22218e5361 class=n-a></a>Zhou HW, Lou SQ, Zhang K: Recovery of function in osteoarthritic chondrocytes induced by p16<sup>INK4a</sup>-specific siRNA <i>in vitro</i> <i>Rheumatology (Oxford).</i> 2004; <b>43</b>(5): 555–66. <a target=xrefwindow id=d22218e5375 href="http://www.ncbi.nlm.nih.gov/pubmed/15026580">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5379 href="https://doi.org/10.1093/rheumatology/keh127">Publisher Full Text </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726113276"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e5388 class=n-a></a>Baker DJ, Childs BG, Durik M, <i> et al.</i>: Naturally occurring p16<sup>(Ink4a)</sup>-positive cells shorten healthy lifespan. <i>Nature.</i> 2016; <b>530</b>(7589): 184–9. <a target=xrefwindow id=d22218e5402 href="http://www.ncbi.nlm.nih.gov/pubmed/26840489">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5406 href="https://doi.org/10.1038/nature16932">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5409 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4845101">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726113276">F1000 Recommendation</a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727547591"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22218e5422 class=n-a></a>Jeon OH, Kim C, Laberge RM, <i> et al.</i>: Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. <i>Nat Med.</i> 2017; <b>23</b>(6): 775–81. <a target=xrefwindow id=d22218e5433 href="http://www.ncbi.nlm.nih.gov/pubmed/28436958">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5436 href="https://doi.org/10.1038/nm.4324">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5440 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5785239">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727547591">F1000 Recommendation</a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d22218e5453 class=n-a></a>Hui W, Young DA, Rowan AD, <i> et al.</i>: Oxidative changes and signalling pathways are pivotal in initiating age-related changes in articular cartilage. <i>Ann Rheum Dis.</i> 2016; <b>75</b>(2): 449–58. <a target=xrefwindow id=d22218e5464 href="http://www.ncbi.nlm.nih.gov/pubmed/25475114">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5467 href="https://doi.org/10.1136/annrheumdis-2014-206295">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5471 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4752670">Free Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d22218e5480 class=n-a></a>Collins JA, Wood ST, Nelson KJ, <i> et al.</i>: Oxidative Stress Promotes Peroxiredoxin Hyperoxidation and Attenuates Pro-survival Signaling in Aging Chondrocytes. <i>J Biol Chem.</i> 2016; <b>291</b>(13): 6641–54. <a target=xrefwindow id=d22218e5491 href="http://www.ncbi.nlm.nih.gov/pubmed/26797130">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5494 href="https://doi.org/10.1074/jbc.M115.693523">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5498 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4807251">Free Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d22218e5508 class=n-a></a>Koike M, Nojiri H, Ozawa Y, <i> et al.</i>: Mechanical overloading causes mitochondrial superoxide and SOD2 imbalance in chondrocytes resulting in cartilage degeneration. <i>Sci Rep.</i> 2015; <b>5</b>: 11722. <a target=xrefwindow id=d22218e5519 href="http://www.ncbi.nlm.nih.gov/pubmed/26108578">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5522 href="https://doi.org/10.1038/srep11722">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5526 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4480010">Free Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d22218e5535 class=n-a></a>Cai D, Yin S, Yang J, <i> et al.</i>: Histone deacetylase inhibition activates Nrf2 and protects against osteoarthritis. <i>Arthritis Res Ther.</i> 2015; <b>17</b>: 269. <a target=xrefwindow id=d22218e5546 href="http://www.ncbi.nlm.nih.gov/pubmed/26408027">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5549 href="https://doi.org/10.1186/s13075-015-0774-3">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5553 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4583998">Free Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d22218e5562 class=n-a></a>Javaheri B, Poulet B, Aljazzar A, <i> et al.</i>: Stable sulforaphane protects against gait anomalies and modifies bone microarchitecture in the spontaneous STR/Ort model of osteoarthritis. <i>Bone.</i> 2017; <b>103</b>: 308–17. <a target=xrefwindow id=d22218e5573 href="http://www.ncbi.nlm.nih.gov/pubmed/28778596">PubMed Abstract </a> | <a target=xrefwindow id=d22218e5576 href="https://doi.org/10.1016/j.bone.2017.07.028">Publisher Full Text </a> | <a target=xrefwindow id=d22218e5580 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5571892">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 04 May 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-325/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-325/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Orthopedic Surgery, Exp. Orthopedics, ZMB/Biopark 1, Am Biopark 9, University of Regensburg, Regensburg, 93053, Germany<br/> <p> <div class=margin-bottom> Susanne Gr&auml;ssel <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Dominique Muschter <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-325/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 04 May 2020, 9:325 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.22115.1">https://doi.org/10.12688/f1000research.22115.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Grässel S and Muschter D. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=24390 data-id=22115 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22115.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-325/v1/pdf?article_uuid=cda9bc96-cd88-418c-a74f-bc7806bc036b" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.22115.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Grässel S and Muschter D. Recent advances in the treatment of osteoarthritis [version 1; peer review: 3 approved] <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):325 (<a href="https://doi.org/10.12688/f1000research.22115.1" target=_blank>https://doi.org/10.12688/f1000research.22115.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=22115 id=mobile-track-article-signin-22115 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22115?target=/articles/9-325/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24390 /> <input name=articleId type=hidden value=22115 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Changhai Ding</strong>, Menzies Institute for Medical Research, University of Tasmania, Australia </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Andrew Pitsillides</strong>, Skeletal Biology Group, Department of Comparative Biomedical Sciences, Royal Veterinary College, University of London, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Frank Zaucke</strong>, Orthopaedic University Hospital Friedrichsheim gGmbh, Germany </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 04 May 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-325/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-325/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=66726-62614></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=66725-62616></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=66724-62615></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-325/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>04 May 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Changhai Ding</strong>, Menzies Institute for Medical Research, University of Tasmania, Australia </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Andrew Pitsillides</strong>, Skeletal Biology Group, Department of Comparative Biomedical Sciences, Royal Veterinary College, University of London, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Frank Zaucke</strong>, Orthopaedic University Hospital Friedrichsheim gGmbh, Germany </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-325/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-325/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in the treatment of osteoarthritis".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-325/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-325/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-325/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Grässel S and Muschter D');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-325/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-325",
            templates : {
                twitter : "Recent advances in the treatment of osteoarthritis. Grässel S and Muschter D, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-325/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in the treatment of osteoarthritis", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in the treatment of osteoarthritis", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/22115/24390")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "24390");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "62614": 1,
                           "62615": 1,
                           "62616": 2,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "1b12c1b0-041d-4a31-b400-757139e529ea";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-325.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-325.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-325.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-325.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-325.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>